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Abstract
Adenosine is a nucleoside that plays an important role in the regulation of contractility in
the hear. Adenosine receptors are G-protein coupled and those implicated in regulation of
contractilty are presumed to act via modulating the activity of adenylyl cyclase and cAMP
content of cardiomyocytes. Adenosine A receptors (AIR) reduce the contractile response ofthe
myocardium to B-adrenergic stimulation. This is known as anti adrenergic action. The A
adenosine receptor (A R) has the opposite effect of increasing contractile responsiveness of the
myocardium. The A R also appears to attenuate the effects of AIR. The effects ofthese
receptors have been primarly studied in the rat hear and with the utilization of cardiomyocyte
preparations. With the increasing use of receptor knockout murine models and murine models of
varous pathological states, it is of importance to comprehensively study the effects of adenosine
receptors on regulation of contractility in the murine heart. The following studies examine the
adenosinergic regulation of myocardial contractility in isolated murne hears In addition
adenosinergic control of contractility is examined in hears isolated from A2AR knockout
animals. Responses to adenosinergic stimulation in murne isolated hears are found to be
comparable to those observed in the rat, with AIR exhibiting an anti adrenergic action and A
conversely enhancing contractility. A significant par ofthe A R effect was found to occur via
inhibition of the AIR antiadrenergic action. A par ofthe anti adrenergic action of AIR has
previously been shown to be the result of protein phosphatase 2A activation and localization to
membranes. Additional experiments in the present study examine the effect of adenosinergic
signaling on PP2A in myocardial extracts from wild type and A R knockout hears. A
activation was found to decrease the activity ofPP2A and enhance localization of the active
enzyme to the cytosol; away from its presumed sites of action. In the A R knockout the
response to AIR activation was enhanced compared with the wild type and basal PP2A activity
was reduced. It is concluded that A R modulation ofPP2A activity may account for the
attenuation of the AIR effect by A R observed in the contractile studies.
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Introduction
Adenosine plays a role in regulating contractility in the hear by activating adenosine
specific receptors. The effects of these receptors mediate primarly the myocardial response to 
adrenergic stimulation. Other fuctions that have been reported include vasodilation
preconditioning and regulation of myocardial remodeling. As such changes in the activation of
adenosine receptors by pharacological or other means may be useful for both the experimental
study of hear function and medical purposes. With the increased use of the murne animal model
for scientific experimentation and the availability of transgenic animals which lack one or more
adenosine receptors it is imperative to study the function and interaction of the adenosine
receptors in the murne hear and also delineate the mechanisms by which these receptors act.
The following dissertation is a study of adenosinergic modulation of contractility in both
wild type and adenosine 2A receptor knockout murine hears. The first work presented focuses
on receptor fuction as seen at the whole organ level using isolated perfsed hears. The second
work presented examines one of the recently proposed mechanisms for the manifestation of the
adenosinergic effects: the modulation of protein phosphatase 2A activity which has been
suggested to be one of the signaling pathways by which adenosine receptors effect alterations in
contractile function of the hear. This investigation also compares the observed effects 
adenosine receptors between wild type and A receptor knockout models. A brief summar of
the known roles of adenosine and its receptors will help to facilitate the integration ofthe new
infonnation obtained into the known framework established through prior study by others.
Adenosine Metabolism in the Heart
Adenosine is a nucleoside that is a product of AMP metabolism. The metabolism of
adenosine in the context of other purnes is outlined in Figure A. Adenosine is metabolized to
~~~
inosine and subsequently hypoxanthine. This pathway is not reversible and leads to eventual
(Usfonnation of hypoxanthine to xanthine and elimination in the fonn of uric acid (21). Along
ths pathway there is an opportity to "rescue" the adenosine metabolites by conversion of
hypoxanthne to inosine monophosphate, which can then be metabolized back to adenosine
monophosphate (AMP). This provides a shunt for adenosine that has entered the irreversible
pathway to inosine a return to the AMP-adenosine pool. An additional pathway for the
metabolism of adenosine is the S-adenosyl-homocystein (49 62). This pathway provides a link
between ATP and adenosine without passing through the adenosine diphosphate (ADP) and
AM states. Instead the A TP is reversibly metabolized to S-adenosyl-methionine, which can
then be metabolized to S-adenosyl-homocysteine. The S-adenosyl-homocysteine in a reversible
reaction then fonns adenosine. This pathway is useful for estimation of cellular adenosine
content and metabolism rates as S-adenosyl-homocysteine does not paricipate in other reactions
nor does it get transported out of the cell (63). In addition to being metabolized, adenosine itself
can also be transported out of the cell (35 87). Once in the interstitial fluid, adenosine can be
transported back into the cell or is deaminated to inosine and fuher metabolized 
hypoxanthine. While in the extracellular comparment adenosine is free to interact with and
activate adenosine receptors on the cell surace (14 82).
Under nonnoxic conditions the level of extracellular (interstitial) adenosine present in the
hear is low. Typical physiological concentrations of adenosine in the hear range 30- 120
pmol/ml. However, adenosine levels are rapidly elevated, to as much as ten-fold increase in
- ponse to pertrbations of cellular metabolism under conditions such as ischemia or hypoxia
:9,32). The stimulus for enhanced adenosine release is a reduction in oxygen levels (3 29).
Under non-pathological conditions adenosine levels can also be elevated as a result of 
,energic stimulation (30).
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Figure A. Metabolism of adenosine in the context of other purnes. ADO-adenosine; A TP-
adenosine trphosphate; ADP-adenosine diphosphate; AMP-adenosine monophospahte; IMP-
inosine monophosphate
rotein co led si nal transduction and modulation o contractili
All adenosine receptors are G-protein coupled (36). As such their effects are believed to
be for the main par manifested via modulation of the activity of adenylyl cyclase and subsequent
changes in cAMP levels (40 93). The G-protein coupled receptor (GPCR) is a combination
of the receptor associated with the G-protein complex which consists of three subunits tenned a
p and y (40). In an inactive state the a subunit is associated with GDP , which upon receptor
activation is replaced by GTP. The a subunit then disassociates from the p and y subunits which
remain together as a py complex (81). Both a -GTP and the py complex play roles in regulating
e activity of adenylyl cyclase (85) and the 
y complex can affect cellular messengers such as
Gkinase and phospholipase 
(PLCB) as well as certain ion chanels (10).
bue to the intrsic GTPase activity of the a subunit, the GTP bound to it is eventually
hydrolyzed and the subunit reassociates with the 
y complex resulting in deactivation (40). There
are multiple types of subunits and G-proteins are classified on the basis of the specific type of
contaied subunits. Further description of various G-protein subtypes is beyond the scope ofthis
thesis, but has been previously described (10 40).
The G proteins associated with the adenosinergic regulation of contractility in the
myocardium are the G and the Gj proteins, characterized by their contained a and aj subunits
and named for their stimulatory and inhibitory properties respectively (81). Stimulatory effects
such as those resulting from B-adrenergic stimulation are thought to be G mediated (68 95)
while inhibitory effects are due to Gj (46). The alterations in cyclic AMP (cAMP) levels that
result from modulation of adenylyl cyclase by the active a-subunits of G-proteins result in
activation or inhibition of protein kinase A (PKA) (26 100) and subsequent changes in
phosphorylation level of proteins important to contractile fuction such as troponin I and
phospholamban (22 86). The G-protein regulation of protein kinase C (PKC) is an additional
pathway for manifestation of adenosinergic effects as well (44 73). Calcium release is also
effected by adenosine (28 91) presumably by both downstream effects of the a as well as 
complex, altering contractility via calcium-dependent mechanisms. A representative diagram of
protein coupled receptor fuction and the fuction some of the key subunits found in the hear
are presented in Figure B.
PKC
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PLC
PI3 Kinase y
Ion channels
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Figure B. protein coupled receptor fuction in regulation of contractility in the hear.
Adenosine A receptors and antiadrenergic action
The A adenosine receptor (AIR) is best known for its anti adrenergic action which is its
ability to decrease the contractile (27 53) and metabolic (15 16) response of the myocardium to
B-adrenergic stimulation (2 18). This effect has been considered to be manifest primarly
through inhibition ofadenylyl cyclase activity (41 83). PKC activation also appears to be
involved in the anti adrenergic effects of AIR as evidenced by its enhanced localization to the t-
tubular system in response to AIR activation in rat ventrcular myocytes (73). However, recently
studies have shown that in addition to modulating adenylyl cyclase activity levels a significant
par ofthe anti adrenergic effect of AIR may be due to its apparent ability to activate protein
l!1(,4
1'1
phosphatase 2A (60), which results in dephosphorylation of proteins important in the regulation
of contractility.
The AIR are also known to be implicated in the transduction mechanisms leading to other
effects. One of these is cardiac preconditioning (1, 71), a phenomenon by which
exposure of the heart to a stimulus (such as brief periods of ischemia in ischemic preconditioning
or activation of certain adenosine receptors) prior to ischemia results in decreased tissue damage
and possibly improved fuctional recovery (55 58). For over a decade adenosine has been noted
to be one of a number of cardioprotective agents released endogenously in response to
ischemic/hypoxic episodes (23 67). This effect most recently has been attrbuted to the
action of specific adenosine receptors including the AIR (51 92). The adenosine activated
R initiates varous proposed mechanisms which provide cardioprotection for the ischemic
hear.
Adenosine A receptors
The A2A adenosine receptor (A R) is known to increase myocardial contractile response
to B-adrenergic stimulation (54 75) indirectly by the attenuation of the antiadrenergic effects
ofthe AIR (78 96). In addition the A R has been noted to directly increase contractility in the
absence of B-adrenergic stimulation (20 96). The major pathway for the effects of A R has
been generally thought to be the modulation of adenylyl cyclase activity (68 96) with a
subsequent alteration in the cellular cAMP level. A cAMP independent mechanism for the
effects of A R has been proposed as well (56) possibly involving Gs-mediated effects on
calcium ion chanels. While with B-adrenergic stimulation the observed enhancement of
contractility by A R activation appears to be closely related to the release of calcium, under
non-adrenergic conditions the same effect appears to be calcium-independent (94) suggesting
that there may be a difference in the predominant pathways by which the A R exerts its effects.
Another major effect of the A R not directly related to contractility is the vasodilation of the
coronar vasculatue which is also in par due to the A R but is considered mainly due to the
activation of A R (75 84).
Other adenosine receptors
The functions ofthe A R) and A3 (A R) adenosine receptors are not nearly as well
defined as those of the AIR and A R. It is thought by some that the effect on contractility of A
receptors is minor (54 75). A R appears to be coupled to the same adenyl ate cyclase/cAMP
pathway as the A R. However it requires much higher levels of interstitial adenosine to become
activated (54). The A R has also been shown important in the regulation of fibroblast activity in
myocardial remodeling which is the reconstrction of myocardial tissue in order to preserve
hear fuction following an infarction (5 8).
While even less is known about the A3 adenosine receptor, research suggests that it plays
litl a strong role in preconditioning and mediation of ischemic damage in myocardium
(12 101). At present there are no published studies focused on the possible effects of
the A3R on myocardial contractility. In a study of anti adrenergic effects of adenosine in isolated
rat hearts administration of A3R did not result in alterations in contractile response to stimulation
of the AIR and A R (78). This observation suggests that contrbution ofthe A3R to regulation
of contractility in the hear is either minor so as not to be observable in a setting of B-adrenergic
stimulation, or does not playa role in the regulation of myocardial contractility altogether.
Adenosinergic modulation of contractility in the intact hear as published in: Contractie
effects of adenosine At and 
A2A receptors in isolated murine hearts American Journal of
Physiology: Hear and Circulatory Physiology 2006 Jan;290(1):H348-
Over the years , considerable attention has been given to the study of adenosine receptor-
mediated regulation of contractility in the hear. Studies published, however, used primarly
isolated rat heart or isolated cardiomyocyte models. While several studies have examined the
effects of adenosine receptors in murine hear, few have focused on contractility as the primar
point of interest, and virtally none have thoroughly explored the interaction ofthe AIR and
R with regard to contractility. The following manuscript is a study of adenosinergic influence
on the contractile fuction observed in the isolated murine hear under several conditions. The
study examines the responses of isolated hearts to adenosinergic stimulation in constant flow and
constant pressure preparations using B-adrenergic stimulation, as well as examines the response
of the heart to brief periods of decreased perfsion in the presence and absence of A
activation.
To compare receptor effects between wild type and the available A2AR knockout model
it would be necessary to establish a basic scheme of receptor function and validate whether the
established infonnation gathered in rat hearts and cardiomyocytes held tre in the murne hear.
The fidings of this study would fonn the basis for the further study of mechanisms by which the
adenosine receptors modulate contractilty. A whole organ approach appeared most appropriate
for this type of study as the ultimate question of interest is the effect of the adenosine receptors
and their interaction with respect to contractility in the physiological setting. As such the isolated
hear provides a setting where the interaction of receptor actions can be studied with minimal
concern of alteration in functions that may occur as a result of cardiomyocyte isolation.
In order to study the effects of the AIR and A R receptors on contractilty in the murne
hear, and compare their effects in a comprehensive maner, the response to B-adrenergic
stimulation was examined under varable adenosinergic stimulation. The use of B-adrenergic
stiulation allowed for enhanced manifestation of the effects of these receptors , as the
contractile response to adenosinergic stimulation in non-adrenergic conditions is fairly small. In
addition because changes in flow and perfusion pressure are known to affect contractilty, and
A2N R modulate vascular resistance, the effects of the A R were examined in the absence of
B-adrenergic stimulation by observing responses to decreased flow while stimulating the
receptor.
Abstract
The adenosine A receptor (AIR) inhibits B-adrenergic-induced contractile effects
(antiadrenergic action), and the adenosine A receptor (A R) both opposes the AIR action and
enhances contractility in the hear. This study investigated the AIR and A R function in B-
adrenergic-stimulated, isolated wild-type and A R knockout murine hears. Constant flow and
pressure perfsed preparations were employed, and the maximal rate of left ventrcular pressure
(L VP) development (+dp/dtmax) was used as an index of cardiac fuction. AIR activation with 2-
chloro-N6-cyclopentyladenosine (CCP A) resulted in a 27% reduction in contractile response to
the B-adrenergic agonist isoproterenol (ISO). Stimulation of A R with 2-P(2-
carboxyethyl)phenethyl-amino- N-ethylcarboxyamidoadenosine (CGS-21680) attenuated this
anti adrenergic effect, resulting in a parial (constant flow preparation) or complete (constant
pressure preparation) restoration of the ISO contractile response. These effects of A R were
absent in knockout hearts. Up to 63% ofthe A R influence was estimated to be mediated
t"r
though its inhibition ofthe AIR antiadrenergic effect, with the remainder being the direct
contractile effect. Furter experiments examined the effects of A R activation and associated
vasodilation with low-flow ischemia in the absence of B-adrenergic stimulation. A R activation
reduced by 5% the depression of contractile function caused by the flow reduction and also
increased contractile perfonnance over a wide range of perfusion flows. This effect was
prevented by the A R antagonist 4-(2-(7 -amino-2-(2- furyl) ( 1 4 )trazolo(2 3-a) (1 , 5)trazin-
ylamino)ethyl)phenol (ZM-241385). It is concluded that in the murne hear, AIR and A
modulate the response to B-adrenergic stimulation with A , attenuating the effects of AIR and
also increasing contractility directly. In addition, A R supports myocardial contractility in a
settng oflow-flow ischemia.
Introduction
Adenosine plays a role in modulating cardiac functions. In the well-oxygenated
myocardium, intracellular levels of adenosine are low, but they rapidly increase in response to
adrenergic stimulation or pathological conditions , such as ischemia and hypoxia (10 , 11). Four
adenosine receptor subtypes have been identified and cloned (13). The adenosine A and A
receptors (AIR and A , respectively) are thought to be paricularly important in the regulation
of cardiac contractility (4 , 7 , 9 , 19 , 26). A2R are also known to be responsible for coronar
vasodilation, with A R considered the main contributor to this effect (27 , 31). A2B receptors are
considered more important to fibroblast regulation (3). The role of adenosine A3 receptors is less
cerain, although they have been linked to preconditioning (24) and have recently been shown to
activate PKB (Ak) in newborn rat cardiomyocytes (14). The AIR is known to exhibit an
anti adrenergic action reducing the contractile responsiveness of the myocardium to adrenergic
s11ulation (1, , 12). A , on the other hand, appears to have a direct inotropic effect on the
myocardi , 26 , 34) by facilitating a greater response to adrenergic stimulation (19, 33) and
an indirect effect by inhibiting the action ofthe AIR (28 34).
Both AIR and A R are G protein-linked receptors coupled to Gj and G , respectively
(13). The effects of these receptors are thought to be mediated either through the modulation of
adenylyl cyclase activity (4, 19) with subsequent activation ofPKA (8 , 13) or via activation of
phosphatidylinositol 3-kinase (PI3K) with the subsequent activation of endothelial nitrc oxide
synthase (eNOS) (17 , 32, 35). A cAMP-independent Gs-mediated mechanism has been proposed
for the stimulatory effects of A R as well (4, 20). Recently PKC has been shown to be
important in the anti adrenergic effect of AIR (25). Other recent studies (21 , 22) have suggested
that a signficant component of the antiadrenergic effect of AIR is a result of protein phosphatase
activation.
The individual effects of AIR and A R on cardiac contractility at the cellular level have
been fairly well characterized. However, their individual actions and the interaction between
them in the intact hear remain topics of active interest. The main purpose of this study was to
examine the interaction of AIR and A R in the perfsed murne hear subjected to B-adrenergic
stimulation. The study also examined the actions of the AIR in the absence of A R with the use
of an A R knockout (A RKO) mouse hear and the effect of A R activation in the absence of
B-adrenergic stimulation. In addition, the influence of A R on ischemic heart fuction was
investigated.
Materials and Methods
Experimental Animals
Six- to eight-week-old wild-type C57BL/6 male mice (WT) were purchased from Sprague-
Dawley. A RKO mice were obtained from a colony maintained by our laboratory. The animals
in this study were maintained and used in accordance with recommendations in the Guide for the
Care and Use of Laboratory Animals, published by the National Institutes of Health (NIH
publication No. 85- , Revised 1996) and evaluated and approved according to the guidelines of
the Institutional Animal Care and Use Committee ofthe University of Massachusetts Medical
School, Worcester, MA.
RKO Generation and Verifcation
The progenitors for the A RKO -/- mice were obtained as a generous gift from Dr. J. F. Chen
of Boston University Medical Center (Boston, MA) and were generated as described previously
by others (2). The homozygous knockout animals used in the present study were offspring of
heterozygous (+/-) breeders. Animals were validated by using DNA isolated from tail tissue with
the use of Qiagen DNEasy tissue kit. Isolated DNA was amplified by PCR using Qiagen Taq
DNA polymerase and primers: 1) AGC CAG GGG TTA CAT CTG TG, 2) TAC AGA CAG
CCT CGA CAT GTG, 3) TCG GCC ATT GAA CAA GAT GG, and 4) GAG CAA GGT GAG
ATG AGA GG. Primers 1 and 2 correspond to the WT A R sequence, whereas primers 3 and 4
correspond to the A RKO sequence. Products of PCR were resolved by using 1 % agarose gel
electrophoresis in Tris-boric acid-EDT A buffer and visualized with ethidium bromide staining
under UV light (WT, 180 bp; A RKO, 330 bp). The agarose gels were used to verify the
genotype of the mice (Fig. 1).
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Figure 1. Agarose gel electrophoresis ofPCR products used to detennine genotype of mice. WT
wild-type (+/+), 180 bp; knockout (KO), A2A-receptor KO (A RKO) (-/-), 330 bp;
heterozygous breeders (+/-), both 180 and 330 bp; MW, molecular weight marker (100 bp
fragment) with 500-100 bands visible top to bottom.
Isolated Heart Preparation
Mice were euthanized by decapitation and hears were excised. After the excision, the
hears were rapidly rinsed in saline at room temperature, mounted on the perfsion apparatus
and persed via the aorta with a physiological saline solution (37 C; PSS) containing (in mM)
118.4 NaCl, 4.7 KCI, 2.5 CaCI2 , 25 NaHC03 , 1.2 KH2P04, 1.2 MgS04 , and 10 dextrose. The
pH of the PSS was maintained at 7.4 by bubbling continuously with a 95% 02-5% C02 gas
mixtue. The developed left ventrcular pressure (L VP) was monitored by a pressure transducer
and a canula tipped with a water-filled polyethylene balloon that was inserted through the mitral
valve after a left atrotomy. Perfusion pressure was monitored by using a transducer connected to
a sidear of the perfusion canula. The heart was paced with 3 V at 480 times/min via leads on
the perfsion canula and the pulmonar arery. All agents were delivered into the perfsion
canula using infusion pumps (model 22, Harard Apparatus, Hollston, MA) at the rate required
0% of perfsate flow rate) to achieve the final desired concentration in the perfsion fluid.
The maximal rates of L VP development (+dP / dtma) and relaxation (-dP / max) were detennined
by differentiation of the L VP signal. All data were recorded by using a model RS-3400 Gould
PQlygraph (Chandler
, AZ).
Protocols
General. For constant flow experiments, the flow rate was adjusted to achieve a L VP of at least
40 mmHg. Flow rates ranged from 2. 5 to 2.9 ml/min. For constant pressure experiments, the
perfusion pressure was held constant at 60 mmHg and the perfusate flow rate was detennined
volumetrcally. Hears were allowed to stabilize for at least 15 min before the initiation of
experimental protocols. In both constant pressure and constant flow experiments, hears failing to
demonstrate a L VP of at least 40 mmHg on stabilization were excluded from fuher study. In
experients with B-adrenergic stimulation, isoproterenol (ISO) was infused for 30 s to achieve a
fial perfsate concentration of 10- M. Adenosine receptor agonists and antagonists were
infused to achieve a final perfusate concentration of 10- M. Preliminar experiments conducted
with the same concentration of ISO at infusion durations of 30 s, 1 min, and 2 min with 15 min
washout did not indicate desensitization of B-adrenergic responsiveness with multiple ISO
infusions (data not shown).
j3-Adrenergic-stimulated hearts.
EFFECT OF A R ACTIVATION ON THE ANTIADRENERGIC EFFECT OF AI After
stabilization, hears were subjected to one 30-s ISO administration, and the peak contractile
responses were recorded. After the hears returned to steady state, infusion ofthe AIR agonist 2-
2h1o
-cyc1opentyladenosine (CCP A) commenced. After 5 min of CCP A infusion, two
. .
additional ISO responses were elicited with a return to steady state between each administration.
CCP A infusion was tenninated after the second ISO response. CCP A and the A R agonist 2-
p(2-carboxyethyl)phenethyl-amino- N-ethylcarboxyamidoadenosine (CGS-21680) were then
administered together for 5 min, whereupon two more ISO responses were elicited while
:cntiuing the CCP A and CGS-21680 infusion. This protocol was conducted with both WT and
RKO hears. To confinn the response to CCP A as AIR specific, in some preparations a
combination ofCCPA and the AIR antagonist 1 dipropyl-8-cyc1opentyl-xanthine (DPCPX)
was administered.
EFFECT OF A R ACTIVATION IN PRESENCE AND ABSENCE OF AIR INHIBITION.
In the first group, after stabilization, hears were subjected to one 30-s ISO
administration, and contractile responses were recorded. On return of contractility to baseline
the A R agonist CGS-21680 was administered for 5 min, and three 30-s ISO responses were
elicited, allowing a return to baseline between stimulations.
In the second group, after stabilization, hears were subjected to one 30-s ISO
administration, and contractile responses were recorded. On retu to baseline, the AI
antagonist DPCPX was administered for 5 min, and two 30-s ISO responses were elicited
allowing a return to baseline after each stimulation. Subsequently, a combination ofDPCPX and
R agonist CGS-21680 was administered for 5 min, and two 30-s ISO responses were elicited
as before.
Reducedflowexperiments. 
For flow reduction experiments, the hearts were initially perfsed at a
rate of3.0 mllmin. The response to a 1 mllmin flow rate decrease was examined under several
experental conditions. These protocols are depicted in Fig. 7.
EFFECT OF A R ACTIV A TION ON CONTRACTILE RESPONSE TO FLOW
REDUCTION.
After stabilization, hears were subjected to thee periods of flow reduction, each of 1 min
duration separated by periods ofnonnal perfsion (3 mllmin) for 3 min, allowing a retu 
baseline contractility (Fig. 7A). At this time, either CGS-21680 or CGS-21680 with the A
antagonist 4-(2-(7 -amino- (2- ful)( I , 4 )trazolo(2 3-a) (1 , 5)trazin- ylamino )ethyl)phenol
(ZM-241385) was administered for 5 min, whereupon the flow-reduction cycle was repeated.
Expected changes in perfsion pressures are depicted in Fig. 7 , B and C.
EFFECT OF CGS-LIKE DECREASE IN PERFUSION PRESSURE ON THE CONTRACTILE
RESPONSE TO FLOW REDUCTION.
In the previous experiments, CGS-21680 elicited a fall in perfsion pressure as a result of
A2A induced vasodilation. To investigate the effect ofthis fall in perfsion pressure
independent of CGS-21680 and fuher differentiate the contractile from the vasodilatory effects
of CGS-21680 the experiments were conducted as follows. The response to a I-ml flow decrease
was examined in addition to a manual reduction in flow that achieved a decrease in perfsion
pressure comparable to that occurrng in response to CGS-21680 administration. After initial
stabilzation, the hear was subjected to three I-min periods of flow reduction separated by
periods ofnonnal perfsion (3. 0 ml/min) for 3 min, allowing a retu of contractile fuction to
prefl reduction levels. The flow was then reduced to the extent required to produce the same
decrease in perfusion pressure as observed with CGS-21680 administration (a decrease of 40--5
mmHg). After stabilization at this new baseline, three more perods of an additional flow
decrease of 1 ml/min were administered. Changes in flow with expected changes in perfsion
pressure are depicted in Fig. 7 , D and E, respectively.
Data and Statistical Analysis
When multiple ISO administrations or flow reductions were used, the responses were averaged.
Data are presented as means:i SE. Data were analyzed with the use of Prism (GraphPad
Softare, San Diego, CA) softare. Additional statistical analysis was done by using StatMost
(Dataxiom, Los Angeles, CA) softare. Data were analyzed using one-way ANOV A, Student-
Newman-Keuls multiple comparson test, and two-tailed t-test where appropriate. Values were
taken to indicate a statistically significant difference at P 05.
Materials
ISO was dissolved in 0. 1 % sodium metabisulfite and diluted to the infusion concentration of 10-
M with MiliQ-treated water. CCPA, CGS-21680 , ZM-241385 , and DPCPX were prepared as 10
mM stock solutions in 100% DMSO and diluted with water to 10- M that was used for infusion
into the perfsion fluid. The resultant perfsion fluid DMSO concentration was not 05%.
Buffer salts were purchased from Fisher Scientific (Fairlawn, NJ). ISO and adenosine receptor
agents CCPA, DPCPX, and CGS-21680 were obtained from Sigma-RBI (St. Louis, MO), and
the A R antagonist ZM-241385 was purchased from Tocris (Ellsvile, MO). Custom primers
and DNA reference ladder were acquired from Invitrogen (Carlsbad, CA). Precast 1 % agarose
mingels with ethidium bromide were obtained from Bio-Rad (Hercules , CA). Qiagen DNEasy
tissue kit and Qiagen Taq DNA polymerase Core kit were purchased from Qiagen (Valencia
RESULTS
fJ-Adrenergic-Stimulated Hearts
Constant flow erfsed wild t hears
Effects of AIR and A R activation in B-adrenergic-stimulated hears were investigated.
In constant-flow perfsed WT hears, the administration ofthe AIR agonist CCP A reduced the
contractile response to ISO stimulation (Fig. 2). Although CCP A reduced the ISO-induced
increase in LVP by 15%, this reduction was not statistically significant (Fig. 2A). However, the
R agonist significantly attenuated the ISO-induced increase in +dP/dtmax by 22% (Fig. 2B).
The ISO responses in the presence ofCGS-21680 (reductions of23% and 28% for LVP and
+dP/dtma, respectively) remained significantly below those observed in the presence ofISO
alone. These values were not significantly different from the CCP A plus ISO responses.
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Figure 2. Effect of AIR and A R activation on left ventrcular pressure (L VP; A) and maximum
rate ofLVP development (+dP/dtmax; B) responses to B-adrenergic stimulation ofthe isolated
constant flow-perfsed murine hear. ISO, isoproterenol (10- M); CCPA, 2-chloro-
cyc1opentyladenosine, AIR agonist (10- M); CGS , 2-P(2-carboxyethyl)phenethyl-amino-
ethylcarboxyamidoadenosine (10- M; CGS-21680). Data are means:l SE for 10 experiments.
*Statistically significant difference from ISO value.
nstant ressure 
erfsed WT hears
Experiments were repeated with constant perfsion pressure rather than constant flow
ig. 3). CGS-21680 administration resulted in an attenuation of the antiadrenergic effect of AI
. ith CCPA treatment the values for LVP (Fig. 3A) and +dP/dtmax (Fig. 3B) with ISO
. -
. stimulation were each reduced by 27%. The antiadrenergic effect of CCP A was fully reversed by
addition of the AIR antagonist DPCPX (data not shown). CGS-21680 attenuated the
antiadrenergic effect of CCP A. In the presence of CGS-21680, CCP A only reduced the ISO-
induced L VP and +dP/dtmax responses by 12% and 18%, respectively. These values were
signficantly different from ISO responses observed with CCP A in the absence of CGS-21680. It
is concluded that the absence of a CGS-21680 effect in the constant flow preparation (Fig. 2)
resulted from the possible influence of a decrease in perfsion pressure resulting from A
induced vasodilation. Although CCP A had no effect on perfusion pressure, CGS-21680
administration resulted in a 35% decrease in perfusion pressure (from 100 mmHg) compared
with values for the control and CCP 
The data were further examined as a percentage increase in +dP/dtmax in response to ISO
stimulation (Fig. 4). With data expressed in this maner, attenuation of the anti adrenergic effect
of CCP A by CGS-21680 was observed for both constant flow and constant pressure
preparations. CCP A reduced the ISO response by 34% and 53% for constant pressure and flow
respectively. However, the ISO responses were decreased only by 10% and 35%, respectively, in
the presence of both CGS-21680 and CCP A.
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Figure 3. Effect of AIR and A R activation
on LVP (A) and +dP/dtma (B) responses to B-
adrenergic stimulation of the isolated, constant
100 pressure-perfused murine hear.
Concentrations used are the following: ISO
10- M; CCPA, 10- M; and CGS , 10- M. Data
are means :i SE for 5 experiments.
*Statistically significant difference from ISO
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Figure 4. Effects of AIR and
R activation on B-
adrenergic-induced contractile
responses in the murne hear.
Concentrations used are the
following: ISO , 10- M; CCP A
10- M; and CGS, 10- M. Data
are means :i SE for 10
experiments using constant
(Const.) flow (Fig. 2) and 5
experiments using constant,
pressure (Fig. 3) perfusion.
*Statistically significant
difference from respective
control (ISO) value;
statistically significant
difference from respective
CCP A value.
Effects of AIR activation in WT versus A RKO hearts. The response to AIR activation, along
with B-adrenergic stimulation in the absence and presence of A R stimulation, was compared
between WT and A RKO hears (Fig. 5). In the WT hear, ISO stimulation resulted in a 244%
increase in +dP/dtmax . In the presence of CCP A, ISO only increased +dP/dtmax by 123%. CGS-
21680 attenuated this antiadrenegic action, as evidenced by an ISO+CCP A response of 151 %.
In the A RKO hear, ISO stimulation resulted in a 253% increase in +dP/dtmax . In the
presence ofCCPA, ISO only increased +dP/dtma by 169%. CGS-21680 in the presence ofCCPA
resulted in an ISO response of only 125%. The ISO-induced increase in +dP/dtmax after
administration of both CCP A and CGS-21680 was not significantly different between A RKO
and WT hears.
300 c: WT Figure 5. Effect of AIR and
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following: ISO, 10- M; CCP A
Ji C 10- M; and CGS , 10- M. Data0'- are means :: SE for 6
experiments. *Statistically
significant difference from ISO
CCPA value; statistically significant
CGS difference from CCPA+ISO
value.
Direct versus indirect effect of A R in WT hearts. To estimate the extent ofthe A R effect
;1"
achieved by a direct increase in contractility, as opposed to its indirect effect through the
inhbition of AI , A R activation in the presence and absence of AIR inhibition was examined
(Fig. 6). ISO alone resulted in a 308% increase in +dP/dtmax (Fig. 6A). In the presence ofCGS-
21680 , this response was increased to 490%, reflecting a 182 percentage-point ( l) increase
from ISO alone. This response is attbutable to both the direct and indirect effects of the A
In the presence of an AIR blockade by DPCPX, CGS-21680 resulted in an increase of only 67
percentage points ( 2) above that of the ISO response (Fig. 6B). It is assumed that the increase
in the ISO response with CGS-21680 in the presence of AIR blockade by DPCPX is due to the
direct effect of A R on contractility and that the direct and indirect effects of CGS-21680 are
independent and additive. The indirect effect of A R acting on the AIR can be estimated by
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subtracting the direct effect from the value representing both
direct and indirect influences ( , Fig. 6C). Detennined in
this maner, the indirect effect of the A R through the
inhibition of AIR is -63% of the total A R effect.
Figure 6. A: effect of A R activation on the contractile
response to B-adrenergic stimulation of constant flow-
perfsed murne hear. , total effect of A R. B: effect of
R activation on contractile response to B-adrenergic
stimulation in presence of AIR blockade. , direct
contractility effect of A R. C: approximation of A R effect
attbutable to its indirect action via AIR. 1 - 
indirect effect of A R via AIR. Concentrations used are the
following: ISO, 10- M; 1 dipropyl-8-cyclopentyl-xanthine
(DPCPX; 10- M), an AIR antagonist; and CGS, 10-
Data are means :i SE for 6 experiments. *Statistically
significant difference from ISO value; statistically
significant difference from DPCPX value.
Reduced Flow Experiments
In the absence of B-adrenergic stimulation, the contractile response to A R activation in
an intact heart is relatively small (5-10%) compared with that at baseline (26). Furthennore
contractile activity is affected by the fall in perfusion pressure inherent with AzA induced
vasodilation in the constant flow preparation. As described in MATERIALS AND METHODS
flow reduction experiments were designed to investigate the effects of A2AR activation in the
absence ofB-adrenergic stimulation (Fig. 7, A-C). Additional experiments were designed to
examine the effect ofthe perfsion pressure decrease that occurs with CGS-21680-induced
vasodilation on contractile function (Fig. 7, D
Baseline flow
1 mUmin
Reduced ftow (RF1)
Repeated 3X baseline to pennit maximal oxygenation and
CGS +/- ZM
and E). A 3.0 ml/min rate of flow was chosen as
mLlin
Reduced ftow (RF1)
Repeated 3X
ff B CGS contractile function without the risk of edema
RF1 that is caused by higher flow rates.
CGS + ZM
Figure 7. Schematic representation of protocol
used to detennine effect of A R activation with
CGS on contractility change occurng with
flow decrease (A) and anticipated perfsion
pressure response (B and C). Schematic
representation of protocol where perfsion flow
was decreased to simulate pressure drop
observed with CGS (D) and anticipated
perfsion pressure response (E). Baseline flow
at stabilization is 3.0 ml/min. RF1 , flow
decrease of 1 ml/min, 1 min duration; RF2 , flow
decrease suffcient to lower perfsion pressure
by 40-45 mmHg. Concentrations used are the
following: CGS , 10- M; 4-(2-(7-amino-2-(2-
ful)(1 , 4Jtrazolo(2 3-aJ(1 , 5Jtrazin-
ylaminoJethyl)phenol (ZM or ZM-241385), and
R antagonist, 10-
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R effect on contractile function with reduced flow. In the absence of CGS-21680, a flow
reduction of 1 ml/min (RFl) resulted in a 32% decrease in perfusion pressure (Fig. 8A), which in
tu led to significant 33%, 30%, and 43% decreases in LVP , +dP/dtmax , and -dP/dtmax
respectively, compared with control values (Fig. 8 , B and C). In the presence ofCGS-21680, a
vasodilation elicited a drop in perfusion pressure of 45 mmHg. This represents a 50% decrease
from the level observed in the absence of the A R agonist. This value was significantly lower
than that observed after the flow decrease (RFl) in the absence ofCGS-21680. In the presence of
CGS-21680 , the LVP and :JdP/dtmax were significantly decreased from control values. However
these contractile parameters with CGS-21680 were significantly higher than those seen durng
RFI without CGS-21680 , despite the lower perfsion pressure. In the presence of CGS-21680, a
1 ml/min flow decrease resulted in a 32% decrease in perfsion pressure compared with the
R agonist alone (Fig. 8A). This reduction in perfsion pressure was associated with decreases
of27% in L VP (Fig. 8B), 23% in +dP/dtmax, and 39% in -dP/dtma (Fig. 8C). To verify the CGS-
21680 response as A R specific, experiments were repeated by using the A R antagonist ZM-
241385. The previously obsered effects ofCGS-21680 were blocked by ZM-241385 (data not
shown). These results indicate that the enhanced contractility observed with CGS-21680 is
specific to A R activation and not a result of the decrease in perfsion pressure.
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Figure 8. Effect of A R activation on effects of a brief flow reduction (RF 1) on perfusion
pressure (A), LVP (B), and :idP/dtmax (C) ofthe constant flow-perfused murine heart. CGS
concentration was 10- M. Data are means:i SE for 6 experiments. *Statistically significant
difference from corresponding control value; statistically significant difference from RFI value
observed in absence of CGS.
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Effect of A R-comparable perfusion pressure reduction on contractile function. Experiments
were conducted to ascertain whether the changes in contractile response to flow reduction were
due to the effect ofCGS-21680 on contractility or as a result of the A R agonist-induced
decrease in perfsion pressure. A protocol was designed with a similar sequence of flow
decreases (RFl). However, instead ofCGS-21680 administration, the flow was manually
reduced (RF2) to the extent required to simulate the decrease in perfsion pressure of 40-45
mmHg that occurs with CGS-21680 (Fig. 8). The changes observed in L VP and :fdP/dtmax
correlated closely with the decreases in perfsion pressure (Fig. 9). The flow reduction RF2
decreased perfsion pressure, LVP , +dP/dtmax, and -dP/dtmax by 36%, 32%, 32%, and 46%,
respectively. The decreases in these four parameters showed no significant differences from
those observed during RF 1.
Furher analysis ofthe data presented in Figs. 8 and 9 reveals that the contractile
depression occurng with RFI is attenuated by CGS-21680. In the absence ofCGS-21680 , RFI
resulted in decreases of 870 (36%) and 763 mmHg/s (43%) in +dP/dtmax and -dP/dtmax
respectively (Fig. 8C). However, after CGS-21680 administration RFI resulted in decreases of
559 (23%) and 535 mmHg/s (38%) in +dP/dtma and -dP/dtmax, respectively. A significant
decrease in response to RFI in the presence ofCGS-21680 may also be observed when
examining the percentage decrease in :fdP/dtmax, resulting from RFI (Fig. 10A). The decreases
(in %) presented in Fig. 10 are the means of the appropriate differences obtained from Figs. 8
and 9. Attenuation of the contractile response to RFI observed in the presence ofCGS-21680
(Fig. lOA) did not occur in preparations using a manual flow reduction to simulate CGS-21680-
induced decrease in perfusion pressure (Fig. 10B). The attenuation ofRFl contractile depression
with CGS-21680 was prevented by the A R antagonist ZM-241385 (Fig. 10C).
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Figure 9. Effect of a CGS-like perfsion pressure drop (RF2) in conjunction with a brief flow
reduction (RFl) on perfusion pressure (A), L VP (B), and :ldP/dtmax (C) in the constant flow-
perfused murine heart. Data are means :I SE for 6 experiments. *Statistically significant
difference from control value; **statistically significant difference from RF2 value alone.
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Figure 10. Percentage decrease of :JdP/dtmax in response to a brief flow reduction (RFl) in the
presence of CGS (A; data from Fig. 8), manual flow decrease sufficient to achieve a perfusion
pressure drop similar to CGS (RF2) (B; data from Fig. 9), or a combination of CGS and ZM (C).
Concentrations used are the following: CGS , 10- M; and ZM, 10- M. RFI +2 , combined flow
decrease ofRF2 and RFI. Data are means :J SE for 6 experiments. *Statistically significant
difference from corresponding RFI value.
Discussion
AlAR and AIR Activation in Presence of j3-Adrenergic Stimulation
The main finding of this study is that A2 R increases the contractile perfonnance of the
myocardium through both direct and indirect mechanisms in the B-adrenergic-stimulated mouse
heart. The actions of A R also support myocardial contractility during reduced flow (low-flow
ischemia). These results extend the previously reported observations that the A R can increase
contractility in intact hearts and cardiomyocytes that are obtained from rats (4, 19 34). The
R and A R interaction has also been reported previously in the rat heart (28) and isolated rat
cardiomyocytes (34), although the exact mechanism by which this occurs remains unkown. The
anti adrenergic action of AIR is thought to be mediated through multiple signaling mechanisms
involving a decrease in adenylyl cyclase activity (18), reduction in calcium transients (12, 28),
and increased PKC translocation (25). The inhibition ofthe AIR effect by the A R may occur
by a modulation of any of these processes. Postulated mechanisms for the effects of the A
have included an activation of adenylyl cyclase (19), calcium-dependent and -independent
mechansms (4, 7 , 33), as well as cAMP-independent mechanisms (4, 20). Based on the data
presented, the effects of the A R can be considered as both direct and indirect. Direct effects
involve the improvement of contractile perfonnance through positive effects, such as an
enhanced activation of adenylyl cyclase, whereas indirect effects involve the inhibition of the
anti adrenergic effects of AIR. The direct effects of A R activation in the intact hear can be
observed independently of B-adrenergic stimulation as described by Monahan et al. (26).
However, the effect of A R activation becomes more pronounced when examined in the
presence of B-adrenergic stimulation.
In both constant flow and constant pressure preparations, A R stimulation was obsered
to attenuate the anti adrenergic effects of AIR activation. The direct increase in contractile
perfonnance observed with the activation of the A R was consistent with previous reports (26)
in which rat hears were used. Interestingly, in the constant perfsion pressure preparation, A
activation appeared to have a greater effect than with constant flow. Although CGS-21680
significantly attenuated the effects of CCP A in both constant flow and constant pressure
preparations, the +dP/dtmax returned to control levels in the constant pressure preparation but
remained significantly below control level in the constant flow preparation after treatment with
CGS-21680 (Fig. 4). This observation is likely due to the increased perfsion flow and vascular
filling seen with constant pressure perfsion. Increased regional tissue distension as a result of
increased vascular filling may result in ventrcular myocytes experiencing enhanced preload
conditions (Water hose/Gregg effect; 16 , 30).
With respect to the attenuation ofthe AIR effect by A , the findings of the present
study confinn those reported by Norton et al. (28) in the rat hear. It is possible, however, to
further delineate the functional aspect ofthe A2AR effect into direct and indirect components. To
estimate the extent to which each of these mechanisms of A R action occurs in the adrenergic-
stimulated mouse hear, the contractile response to CGS-21680 stimulation of the A R was
compared in the presence and absence of AIR inhibition. The ISO response in the presence of
CGS-21680 is assumed to be affected by both mechanisms in an additive fashion, i. , A R is
able to both inhibit the manifestation of AIR effects and increase contractility directly. The direct
action of A R can be revealed by pretreating the hear with the AIR antagonist DPCPX before
R stimulation. The resulting increase in the contractile response to ISO in this case is due to
the direct effect of the A R on contractilty. The observed increase in the ISO response with
CGS-21680 was reduced after pretreatment with DPCPX (Fig. 6). The additional increase in the
ISO response was approximately one third of the response seen when CGS-21680 was
administered without prior AIR inhbition ( 1 vs. 2; Fig. 6). These calculations suggest that a
major par ofthe R effect is mediated through the inhibition ofthe AIR (indirect effect) as
opposed to its direct effect on contractility. This conclusion is consistent with the observation
that A R activation only has a minor effect on contractility (5-10%) in the absence of
adrenergic stimulation. In the presence of adrenergic stimulation where the AIR plays a
significant role in attenuating the adrenergic response, the A R exerts a more profound
inhibitory effect on the antiadrenergic action of AIR. Thus the interaction of the A R and the
R is of greater importance in the adrenergic-stimulated hear.
R and A R Stimulation Response: Comparing Knockout and WT Hearts
There were two findings of interest when comparng the responses of AIR and A
activation in WT and A RKO hears. First, the observed anti adrenergic response to AI
activation was greater in the WT than in the A RKO hearts (Fig. 5). The ISO responses
observed were not markedly different between WT and A RKO hears, whereas there was
approximately a 50 percentage point difference between the average ISO response levels in the
presence of CCP A. These findings conflct with previous reports indicating that in a WT rat
hear, the inhibition of A R with ZM-241385 increased the antiadrenergic effects of AI
activation (28). The absence of the A2AR in the A RKO hear should result in a situation similar
to that where the A Rs are inhibited pharacologically. It would be expected that the A RKO
would be more responsive to the anti adrenergic effect of AIR. However, the opposite was
obsered in the present experiments. It is possible that this is due to a modification of AI
signaling in the A RKO. However, the study of vascular smooth muscle responses to adenosine
analogs in the A RKO mouse suggested no adaptations (29). The reason for the presently
obsered enhancement ofthe AIR response in A RKO hears remains to be explored.
The second notable difference between the WT and A RKO hears was the response to
the CGS-21680 and CCPA combination. In the WT hearts , CGS-21680 produced an increase in
contractile response to ISO from that observed in the presence of CCP A, as expected. However
in the A RKO hears, there was a further decrease in ISO contractile response after treatment
with CCPA and CGS-21680 together. A possible explanation is an interaction between CGS-
21680 and the AIR. A binding ofCGS-21680 to tissues in an AI dependent maner has been
reported in the mouse brain (15 , 23). The exact natue of this interaction between CGS-21680
and AIR remains unown. The observed decrease in the ISO contractile response seen with
CGS-21680 beyond that with CCP A alone may occur in the A RKO hears, because CCP A
together with CGS-21680 activates the AIR to a greater extent.
R Supports Myocardial Contractility With Low-Flow Ischemia
To study the importance of A R activation in providing contractile support in a
nonadrenergic-stimulated hear and the role of vasodilation in the contractile effects of 
activation, an experimental protocol was used where the response to brief periods of low-flow
ischemia was examined. The effect of A R on contractility in the absence of adrenergic
stimulation is small. In the curent protocol, where a decrease in flow rather than adrenergic
stimulation was applied, it was possible to examine the effect of A R activation on contractility
even in the absence of adrenergic stimulation. There were two main findings in this series of
experiments. First, A R activation resulted in a higher level of observed contractile perfonnance
at a given perfusion pressure. After the administration of CGS-21680 , vasodilation resulted in a
perfsi pressure significantly lower than that observed with the l-ml flow decrease (RFl , Fig.
8A). Despite this result, the observed L VP and :ldP/dtma were both higher than that observed
after RFI in the absence ofCGS-21680. This indicates that in the presence of A R stimulation
myocardial contractility is enhanced as evidenced by the increased L VP and :ldP/dtmax at a given
perfsion pressure. This effect was fully reversible with the A R antagonist ZM-241385 and
thus was attbutable to A
The second observation of interest was that the actual decrease in contractility observed
durng the administered periods oflow-flow ischemia (RFl) was significantly less in the
presence of A R stimulation with CGS-21680. This difference was most clearly visible with
respect to :ldP/dtmax (Fig. 10). To detennine whether this observation was due to A
contractile effects, as opposed to the result of the decreased perfsion pressure resulting from
CGS-21680-induced vasodilation, another series of experiments used a manual decrease in flow
(RF2, Fig. 9) to simulate the decrease in persion pressure caused by CGS-21680
administration. This manual perfsion pressure decrease did not attenuate the extent of
contractile fuction reduction seen with flow drop RF 1. In fact, the attenuation of response to
flow reduction was only seen with CGS-21680 and was prevented by the A R antagonist ZM-
2413 8.
In summary, this study has found that the A R enhances the contractile response to B-
adrenergic stimulation in the murine heart directly through an effect on contractility and
indirectly by an attenuation of the anti adrenergic actions of the AIR. In addition, A R activation
supports contractile fuction durng low-flow ischemia, resulting in an increased contractile
function at the given reduced perfusion pressure.
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Supplemental Material
Additional preliminar study and supporting experiments for the preceding manuscript are
included in this section.
Refractoriness of repeated isoproterenol (ISO) stimulation in isolated hearts
One of the concerns with the protocols utilized in the present study is the employment of
repeated ISO stimulations. This protocol design allowed each heart to be used as its own control.
The alterations seen in contractile response to B-adrenergic stimulation following adenosine
receptor activation could be then compared immediately in each hear during the experiment to
verify the appropriate response to the agent administered. However, with repeated B-adrenergic
stimulation desensitization is known to occur (45 90) and the myocardial increase in contractility
may be reduced following multiple stimulations. In an experment designed to examine effects of
adenosinergic modulation of contractility, such desensitization effects would result in
confounding of the parameter examined. To verify that four ISO administrations in a typical
protocol would not result in notable desensitization, experiments were carred out exposing the
hear to repeated ISO stimulations on a time scale that was used in the other studies. In addition
longer infusions of ISO were also used with the rationale that if desensitization would not be
significant following 1 or 2 min ISO infusions, the 30-s ISO infusions would be even less likely
to produce desensitization. The results of a representative desensitization study are presented in
supplementary figue S 1. Although the response to the second stimulation was observed to be
11 % lower than the first, this decrease was not statistically significant. Additional stimulations
subsequently resulted in only a further 6% decrease by the 5
th ISO administration. No significant
desensitization occurred following five ISO infusions of2-min duration. Because only four 30-s
infusions per heart were actually used in the studies of contractility outlined in the preceding
manuscript, it is concluded that refractoriness to ISO stimulation doesn t influence the
interpretation of obtained data.
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Figure Sl. Typical contractile response of an isolated constant flow perfused WT murine hear
to multiple 2-min stimulations with isoproterenol (ISO , 10- M). The hear is allowed to stabilize
following each ISO administration.
Specifcity of AzR antiadrenergic response
In order to verify the reduction in adrenergic-induced contractile responses following
administration of CCP A as AIR specific, studies were cared out using the AIR antagonist
DPCPX to block the anti adrenergic action of AIR activation (Supplementar Figure S2). DPCPX
administration restored the contractile response to ISO stimulation to levels comparable with
those observed in the absence of AIR activation. These findings were noted in direct
measurements ofLVP (Fig. S2 A) and +dP/dtmax (Fig. 82 B) as well as in the calculated
percentage increase of +dP/dtmax (Fig. S2 C). These results indicate that the decrease in
contractile response to ISO stimulation observed following CCP A-induced AIR activation is
indeed specific to the AI
As mentioned previously, there are no alterations in contractile function at baseline prior
to ISO stimulation as a result of AIR stimulation. The observed L VP and +dP/dtma levels appear
fairly consistent at all points in the experiment. In the isolated hear model, the administration of
an AIR agonist results in bradycardia as the AIR receptor can result in less effcient
atroventrcular conduction (42). However, in a hear being electrcally paced this effect of AI
activation is not visible. With ISO stimulation the anti adrenergic effect of AIR activation is
clearly evident. These observations suggest that the isolated perfsed hear is an appropriate
model for study of adenosinergic modulation of contractile response to adrenergic stimulation. In
order to study adenosinergic influence and receptor effect interactions on contractilty in non-
adrenergic conditions it would be advisable to either use an alternate stimulus, or conduct the
appropriate studies in isolated cardiomyocytes where the response to adenosinergic stimulation
can be measured with greater precision on a smaller scale.
200
180
160
C) 140
E 120
E 100
D: 80
:; 60
.. 40
12500
10000
7500
5000
ii 2500
600 C
.J C 500
"C .
il 10 400
"C "S
5 E 300
GI :;
:Q 200
GI 
t) 100C -
- '
:- 0
q, (; q, 
v q,
q  
.; 9,
q, 
Figure S2. Effect ofisoproterenol (ISO 10- M) stimulation on L VP (A), +dP/dtmax (B) and
percentage increase in +dP/dtmax (C) in an isolated, constant pressure perfused, murine heart
preparation in the absence and presence of CCP A or a CCP A/PCPX (10- M) combination.
Data presented are means:: SE for 8 experiments. * denotes statistically significant difference
from the corresponding control value; ISO in (A) and B), Ctrl in (C). 
denotes statistically
significant difference from the CCP AlISO value in (A) and (B), and from the CCP A value in
(C).
Effects of A R stimulation are dependent upon adenosinergic-induced changes in perfusion
pressure
One of the initial observations made durng the present study was that under constant
flow conditions A R activation did not appear to attenuate the anti adrenergic effects of AI
activation. (See Figure 2 in preceding manuscript.) As described in the preceding manuscript
this finding was subsequently attbuted to the decreased perfsion pressure resulting from A
activation-induced vasodilation. As demonstrated in supplementar Figure S3 , the activation of
R with CCP A does not have a notable effect on the perfsion pressure. However, following
the administration of both CCP A and CGS-21680 there is a clear reduction in the measured
perfusion pressure. Thus A R stimulation elicits a vasodilation of the coronar vasculatue. The
observed vasodilatory effect resulted in a 25% decrease in perfsion pressure from the control
value.
The decrease in the perfusion pressure following A R activation results in lower
absolute L VP and ::dP/dtmax measurements makng direct comparison ofthese values difficult
between hears treated with CGS-21680 and those treated with other adenosinergic agents.
Ultimately this issue was resolved via comparson of percentage increases in contractile fuction
(i.e. +dP/dtmax) as opposed to direct comparson of measured LVP or dP/dtma values. As
discussed in the manuscript, this type of analysis results in the same trends visible between the
constant flow and constant pressure preparations once the analysis is applied. (See Figues 3 and
4 in preceding manuscript.) An additional conclusion that can be made from these observations
is that the decreased perfusion pressure observed in the presence of A R stimulation-induced
vasodilation does not appear to effect contractile function in the same way as a decrease in
perfsion pressure resulting from decreased flow. The heart is able to demonstrate a higher level
of contractile response to adrenergic stimulation in the presence of A R stimulation despite the
lower observed perfusion pressure, whereas contractile function is not preserved in the absence
of A R stimulation. These findings are further supported by the results of the flow decrease
experments.
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Figure S3. Effect ofCCPA or CCPAlCGS (10- M) combination on the average perfsion
pressure in a constant flow perfsed, isolated murine hear preparation. Data presented are means
:i SE for 10 experiments. * denotes statistically significant difference from the corresponding
control (Ctrl) value.
Specifcity of A R-mediated attenuation of response to flow reduction
One of the main findings of the reduced flow experiments was that A R activation
results in an attenuated contractile depression in response to flow reduction. Hears pretreated
with CGS-21680 displayed a smaller reduction in LVP as well as :idP/dtmax in response to a flow
decrease (See Figures 8 and 10 in preceding manuscript.). In order to confinn these effects as
specifi to CGS-21680-mediated A R activation, experiments were conducted to block this
effect by utilizing a combination of both CGS-21680 and ZM-241385 , an A R antagonist. The
results are summarzed in supplementary Figure S4. Treatment of the hears with both CGS 
and
ZM resulted in no observable differences between control and treated groups for both perfusion
pressure (Fig. S4 A) and L VP (Fig. S4B).
These findings show that the attenuation of contractile response to flow reduction
observed with CGS-medicated A R activation is receptor specific. In addition the absence of
observed perfsion pressure differences suggests that the addition of ZM is effective in blocking
CGS from activating the A , as one of the first and most easily noted responses observable
following A R activation is a profound decrease in perfsion pressure.
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Figure S4. Effect of a flow reduction of 1 ml/min (RFl) on perfsion pressure (A), and L VP (B)
in an isolated, constant flow perfsed, murine hear preparation in the absence and presence of a
CGS/ZM (10- M) combination. Data presented are means:i SE for 6 experments. * denotes
statistically significant difference from the corresponding control value; Ctrl and CGS/ZM
respectivel y.
Summary of Key Findings
1) AIR and A R play an important role in modulating the response to B-adrenergic stimulation
in the murine hear.
2) AIR exhibits an anti adrenergic effect upon activation, reducing contractile response to B-
adrenergic stimulation. Interestingly this effect appears to be less pronounced in the A
knockout animals.
3) A R attenuates the anti adrenergic action of AIR by inhibiting the AIR effect and also by
directly increasing contractility.
4) In the setting of decreased coronar flow A R activation results in enhanced contractile
perfonnance. Contractile activity observed to be higher for a given perfusion pressure in the
presence of A R activation.
5) A R activation decreases the acute response to decreased coronary flow, maintaining a
higher level of contractile function. This suggests that the activation of this receptor may be a
cardioprotective mechanism in conditions of ischemia or hypoxia.
Adenosinergic influence on protein phosphatases: role of PP2A as submitted for publication in
the manuscript entitled: Adenosine At and 
Receptor Regulation of Protein Phosphatase
2A in the Murine Heart" submitted to American Joural of Physiology: Hear and Circulatory
Physiology 2006 , 22 May. In review.
The best known mechanism for the modulation of cardiac contractility by the AIR and
R is the inhibition or activation of adenylyl cyclase, with subsequent alterations in the cAMP
content ofthe cardiomyocyte (36 96). However, this pathway is not exclusive and a number of
other mechanisms have been proposed as well (56 94). Ifthe contractile response to B-adrenergic
stimulation and its enhancement by the A R is mediated in par by the phosphorylation of
contractile and regulatory proteins (22) it is conceivable that the antiadrenergic effect In fact one
of the more recent findings is that a significant part ofthe AIR antiadrenergic effect is mediated
by the activation of protein phosphatase 2A (PP2A) (60 61).
From previous observations of the effects of the A R in both literatue and the study
presented in the preceding manuscript, it was concluded that the A R is able to attenuate the
effects of AIR (78). It would be logical to consider whether one of the focal points for AIR and
R interaction is co-regulation ofthe activity ofthis protein phosphatase. Thus the goal ofthe
following manuscript was to explore the possible effects of the A R on PP2A and elucidate the
interaction of the AIR and A R at this level. In addition, the A R knockout model was utilized
to study the effects of AIR on PP2A in the absence ofthe influence of the A
Previous research focusing on AIR-mediated modulation ofPP2A activity utilized the
quantification of the carboxymethylation state of the enzyme as an indicator of its activity level.
It was presumed that once the enzyme was appropriately modified it would translocate to the site
of action and dephosphorylate its target proteins. This observation was supported by measured
changes in the phosphorylation state of contractile proteins within the cardiomyocytes (60).
While this approach is quite fuctional , in the following study the goal was to take this approach
one step further and actually measure the activity ofthe PP2A directly. In order to achieve this
an assay was utilized where the PP2A in myocardial extracts was allowed to dephosphorylate a
specific substrate under conditions optimal for the activity of this phosphatase. This method
allows a more direct examination of the activity ofPP2A as there is no longer an assumption
about its activity state, but rather the activity is explicitly measured.
Abstract
Adenosine plays a role in regulating the contractile fuction of the hear. This includes a
positive inotropic action via the adenosine A2A receptor (A R) and an inibition of B
adrenergic receptor-induced inotropy (antiadrenergic action) via the adenosine Al receptor
(AIR). Phosphatase activity has also been shown to influence contractile function by affecting
the level of protein phosphorylation. Protein phosphatase 2A (PP2A) plays a significant role in
mediating the AIR anti adrenergic effect. The purpose of this study was to investigate the effects
of A R and AIR on the activities ofPP2A in tissues from wild type (WT) and A R knockout
RKO) hearts. PP2A activities were examined in myocardial cytoplasm and membrane
fractions by measuring phosphate released from a phosphorylated substrate. In WT hears
treatment with the AIR agonist CCP A resulted in an increased PP2A activity and an enhanced
localization of active PP2A to the membrane fraction. The A R agonist CGS-21680 decreased
PP2A activity and enhanced PP2A localization to the cytosolic fraction. In A RKO hears the
response to AIR activation was markedly enhanced whereas the response to A R activation was
negligible. In addition control and CGS-21680 treated A RKO hears demonstrated a
significantly reduced PP2A activity level and localization to the membrane fraction. These data
show that A R and AIR regulate PP2A activity thus suggesting an important mechanism for
modulating myocardial contractility.
Introduction
Adenosine (ADO) plays an important role in modulating cardiac function by regulating
the contractile responsiveness ofthe myocardium to adrenergic stimulation (8 40). Ofthe four
subtypes of adenosine receptors identified, the A and A2A receptors (AIR and A
respectively) are thought to be primarly involved in this process (10 43). The
decrease in contractile response to adrenergic stimulation elicited by AIR activation is known as
an anti adrenergic action (2 9). The A R have been shown not only to attenuate this
anti adrenergic action (37 45), but also to increase contractility directly (11 45) and
independently of B-adrenergic stimulation (33).
Contractility in the myocardium is closely related to the degree of phosphorylation
achieved by varous cellular proteins. These include proteins such as troponin 
phospholamban
and others that are involved in force development, calcium homeostasis, and mechanisms of
receptor signaling (12 44). The anti adrenergic action of AIR has been shown to
reduce the level of phosphorylation attained by a number of cellular proteins during adrenergic
stimulation (16 29). This action of adenosine is thought to be mediated, in par, by Gj
proteins with subsequent inactivation of adenylyl cyclase previously activated by BI-adrenergic
receptors (BIR) (7 28). The resultant reduction in cellular cyclic AMP levels sequentially reduces
cellular protein phosphorylation by decreasing the BIR activated protein kinase A (PKA) activity
18). Another protein kinase, PKC has also been reported to be important in the anti adrenergic
action of AIR (32). Thus reduced phosphorylation oftarget cellular proteins is one mechanism
by which adenosine exerts an anti adrenergic action.
Enhanced dephosphorylation of proteins previously phosphorylated in response to BI
stiulation can be proposed to reduce the adrenergic-induced contractile response.
Pharacological inhibition of protein phosphatases with inhibitors such as canthardin has been
shown to result in an enhanced protein phosphorylatio and increased contractile force in
myocardial preparations (13 34-36). In addition, studies have demonstrated that while
overexpression of the catalytic subunit of the serine/threonine protein phosphatase 2A (PP2A)
impairs cardiac function (20), elevated expression of protein phosphatase inhibitors PPI- l and
PPI-2 results in cardiac function enhancement (24 38). Recent studies have reported that the
R is able to activate the protein phosphatase 2A (PP2A) and alter its localization within the
cell resulting in the decreased phosphorylation of proteins related to contractile function (29 30).
Although reports suggest that AIR mediates its effects in par by the activation ofPP2A
(29 30), it is presently unkown whether A R modifies AI induced changes in PP2A activity,
directly decreases the PP2A activity or both. An additional rationale for the following study is
that A R has been shown to modulate neutrophil superoxide anion generation through
activation of serine/threonine protein phosphatases (39). Such a finding suggests the possibility
that A R may have an effect on PP2A in the myocardium as well.
The purpose ofthe following study was to examine the effects of A R and AI
stimulation on the PP2A activity in ventrcular samples from both wild type (WT) and A
knockout (A RKO) mice. The interaction between these two adenosine receptor subtypes in
affecting PP2A activity was also examined. In addition the effects of A R and AIR stimulation
on the phosphorylation state ofTyr 307, one ofthe regulatory sites ofPP2A (23), were studied.
aterials and Methods
eriental Animals
Six- to eight-week-old wild type C57BL/6 male mice were purchased from Taconic
Fars (Hudson, NY). A RKO mice were obtained from a colony maintained by our laboratory
and were generated and genotyped as previously described (4 43). Briefly, total DNA was
isolated from tail clippings, amplified using PCR, resolved using electrophoresis on ethidium
bromide containing agarose gels and visualized under UV ilumination. The animals in this study
were maintained and used in accordance with recommendations in the 
Guide for the Care and
Use of Laboratory Animals published by the National Institute of Health (NIH Publication No.
85- , Revised 1996) and evaluated and approved according to the guidelines of the Institutional
Animal Care and Use Committee of the University of Massachusetts Medical School, Worcester
MA.
Isolated Hear Pr aration
Mice were euthanized by decapitation and the hears were excised. Following excision
the hears were rapidly rinsed in room temperature saline, mounted on the perfsion apparatus
and perfused via the aorta with a physiological saline solution (PSS) containing (in mM): 118.4
NaCl , 4.7 KCl, 2.5 CaCh, 25 NaHC03, 1.2 KH P04, 1.2 MgS04, and 10 dextrose. The PSS
temperature was held at 37 C and the pH was maintained at 7.4 by bubbling the solution
continuously with a 95% 02-5% C02 gas mixture. The perfsion flow rate was held constant at
8 ml/min. The developed left ventrcular pressure (L VP) of the hears was monitored using a
canula tipped with a water-filled polyethylene balloon connected to a pressure transducer and
inserted into the left ventrcle through the mitral valve following a left atrotomy. Perfusion
pressure was monitored using a transducer attached to a sidear of the perfusion assembly.
Pacing of the heart (3 V at 480 stimulations/min; Grass, Quincy, MA) was accomplished via
leads on the perfusion cannula and the pulmonar arery. All agents were infused into the
perfsion canula using an infusion pump (mode122, Harard Apparatus, Hollston, MA)
operating at 1.0% ofthe perfusate flow rate to achieve the final desired perfusate concentration.
Hears were submerged in 37 C PSS for the duration ofthe perfusion. Data was recorded using a
model RS-3400 Gould polygraph (Chandler, AZ). Hears failing to develop a L VP of at least 40
mmHg were excluded from fuher study. The hears were perfused with PSS containing the
agent of interest for a period of 15 min. The hear was rapidly removed from the perfsion
apparatus, freeze-clamped and stored in liquid nitrogen prior to being assayed.
Effects of AIR and A R on PP2A activit
Isolated heart protocols
PP2A activities were assayed in ventrcular myocardium from WT hears that were
perfsed for 15 min with PSS containing the following agents: 10- M A R agonist P(2-
carboxyethyl)phenethyl-amino- N-ethylcarboxyamidoadenosine (CGS-21680) alone, 10-
R agonist 2-chloro- -cyclopentyladenosine (CCPA) alone, both CCPA and CGS-21680
together, or the 10- M A R antagonist 4-(2-(7-amino- (2-furyl)(1 4)traz lo(2
a)(I 5)trazin- ylamino)ethyl)phenol (ZM-241385). Control hears were perfsed with agent-
free PSS for the same period oftime as the treated hears prior to freeze-clamping. In addition
PP2A activity was assayed in A RKO myocardium perfsed in the absence (control) or
presence of 10- M CGS- 21680 or 10- M CCP A.
Preparation of Myocardial Fractions
Ventrcular myocardium was homogenized in 2 mL of ice-cold buffer containing 20 mM
HEPES (pH 7.4), 1 mM EDT A, 0. 1 mM DTT, 0. 1 mM benzamidine and 10 J.g/ml soybean
trsin inhibitor using a Polytron at a speed setting of 5 (two 10-sec bursts with a 15 sec pause
between bursts). A 600 J.L aliquot of the homogenate was diluted with an equal volume ofthe
homogenization buffer and centrfuged with a microfuge for 20 min at 12 000 x g. The resulting
supernatant is tenned the cytosolic fraction containing the PP2A located primarly in the cellular
cytoplasm. The pellet was resuspended in 400 J.L of homogenization buffer and held on ice for
20 min prior to centrfugation for 20 min at 12 000 x g. This supernatant was tenned the
pariculate fraction containing PP2A solubilized from the cell membranes. All samples were
maintained at 4 C during processing.
Assay of phosphatase activity
Superatants from both cytosolic and particulate fractions were assayed for PP2A activity
using the Promega serine/threonine phosphatase assay kit (Promega, Madison, WI). Briefly, 350
J.L aliquots of the supernatants were passed though Sephadex G-25 resin spin columns by
centrfugation at 600 x g for 4 min to remove endogenous phosphate. Phosphatase activity was
detennined by the release of free phosphate from a phosphorylated substrate. The phosphate
released was detected colorimetrcally by the fonnation of a molybdate:malachite
green:phosphate complex. Interference ofPPl and PP2B activity was minimized with the use of
a PP2 selective substrate and by inclusion of EGT A, respectively, in the reaction mix. The
protein content ofthe samples was detennined using a BCA protein assay (Pierce Biotechnology,
Rockford IL).
Phos lation state of the PP2A T 307 re lato site
The phosphorylation state of the Tyr 307 site on PP2A was detennined with an ELISA
assay using a mouse anti-phospho-PP2A (Tyr307) primar antibody and a secondar goat anti-
mouse IgG antibody conjugated to horseradish peroxidase (Upstate Biotechnology, Lake Placid
NY). Control ventricular samples from WT hearts were compared to those treated with 10-
CGS-21680 or 10- M CCP A. Samples were homogenized in a buffer containing 50 mM Na C03
(pH 9.6). A 96-well microtiter plate was layered with ventrcular homogenate (90 Ilg
protein/well). Then the plates were incubated at 4 C overnight. Following this incubation the
wells were rinsed twice with a wash buffer containing 150 mM NaCI, 20 mM TRIS (pH 7.4) and
05% (by volume) Tween-20. The wells were then blocked for 2 hrs at 4 C with 5% nonfat 
milk in wash buffer. Blocking solution was removed, the wells were rinsed twice with wash
buffer and primar antibody at a dilution of 1 :300 in blocking solution was added (100 ilL /well).
Plates were then incubated for 1 hr at room temperatue. Primar antibody was removed and the
wells were rinsed twice with wash buffer. Secondar antibody was added at a dilution of 1 :500
in blocking solution and incubated 1 hr at room temperatue. Secondar antibody was removed
and the wells were rinsed four times with wash buffer and once with a Phosphate-Citrate buffer
containing 24.3 mM citrc acid and 51.4 mM Na P04. ABTS chromogen substrate solution (100
ilL; Zymed Laboratories, South San Francisco, CA) was added to each well and incubated at
room temperature for 55 min. The absorbance ofthe developed color was read using a plate
reader with a 405 nm filter.
Data and Statistical Anal sis
Results are presented as means:! SE. Data were plotted using Prism (GraphPad Softare
San Diego , CA). Statistical analysis was perfonned using StatMost (Dataxiom, Los Angeles
CA). Statistical tests applied include ANOV A and Student-Newman-Keuls multiple comparson
test. Standard errors for the difference in means as seen in Fig. 3 was calculated as the square
root of the sum of varances of the sample means (1). Statistical significance was defined at P .c
05.
Materials
All adenosine receptor agents were prepared as 10 mM stock solutions in 100% DMSO
and diluted with miliQ-treated water to 10-4 M that was used for injection into the PSS. The
resulting concentration ofDMSO in the perfsion medium did not exceed 0.01 %. Buffer salts
and assay multiwell plates were purchased from Fisher Scientific (Fairlawn, NJ). CCP A and
CGS-21680 were obtained from Sigma RBI (St. Louis MO) and ZM-241385 was purchased
from Tocris (Ellisvile, MO).
Results
Effects of A R and AiR on PP2A activity in WT hearts
Administration ofthe A R agonist CGS-21680 to WT hears decreased PP2A activity by
16% in the myocardial pariculate fraction (Fig lA). Conversely, the AIR agonist CCP A resulted
in a significant 12% increase in PP2A activity. Treatment ofthe hears with both CCP A and
CGS-21680 reduced the PP2A activity level 25% below that of control and 32% below that
observed with CCP A alone. This value was not significantly different from the phosphatase
activity observed with CGS-21680 alone. To investigate the effect of pharacological inhibition
of A R as compared with effects of receptor knockout as shown below, hears were treated with
the A R antagonist ZM-241385. The antagonist resulted in a 36% decrease in activity as
compared to the control value. In the cytosolic fraction ofWT hearts (Fig IB), the effects of
adenosinergic stimulation were similar to those of the particulate fraction, though less
pronounced. Treatment of the hearts with CGS-21680 and CCP A separately resulted in a 5%
decrease and 10% increase in PP2A activity, respectively. However these changes were not
statistically significant. Treatment of the hears with CGS-21680 and CCP A together also did not
result in significant changes in activity from that of control. However, this PP2A activity was
decreased by 10% from the level seen with CCPA alone. Treatment ofthe hears with ZM-41385
resulted in a 28% decrease from control. The observed PP2A activity levels were noted to be
higher in the pariculate fraction compared with those in the cytosolic fraction for control, CCP A
and ZM-241385 groups. These results suggest that the A R modulates the activity ofPP2A both
directly and via an interaction with the AI
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Figure 1. Effects of AIR and A R stimulation on PP2A activities in pariculate (Panel A) and
cytosolic (Panel B) fractions of ventrcular myocardium from wild type (WT) murine hearts.
CGS , A R agonist 2-(2carboxyethyl)phenethyl-amino-5' -N-ethylcarboxyamidoadenosine (10-
M; CGS-21680); CCPA, AIR agonist 2-chloro-.N-cyclopentyladenosine (10- M); ZM, A
antagonist 4-(2-(7 -amino-2-(2- ful)( 1 , 4 )trazolo(2 3-a) (1 , 5)trazin- ylamino )ethyl)phenol
(10- M; ZM-241385). Data are means:f SE for 4-9 hears. * denotes statistically significant
difference from control (Ctrl) value; t denotes statistically significant difference from CCP 
value.
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Effects of A R and AjR on PP2A activity in A RKO hearts
Administration of CGS-21680 to hears obtained from A RKO animals (Fig 2) resulted
in a 7% decrease in PP2A activity in the cytosolic fraction, whereas in the pariculate fraction
CGS-21680 had no effect on the phosphatase activity. CCP A administration caused a 16%
increase in PP2A activity. In the pariculate fraction both control and CGS-21680 treated hearts
displayed significantly lower PP2A activity compared with their respective cytosolic
counterparts. CCP A treatment of these hears produced a 205% increase in pariculate PP2A
activity. This value was 15% higher than that observed in the cytosolic fraction with CCP 
Comparison ofWT and A RKO responses to adenosinergic stimulation
Major differences in the PP2A response to AIR or A R activation between WT and
RKO hears are most readily compared in the parculate fractions as summarzed in Figure 3.
In WT hearts treatment with CGS-21680 resulted in a decrease in PP2A activity, whereas in the
RKO CGS-21680 had no significant effect. Both WT and A RKO hears demonstrated an
increase in PP2A activity in response to CCP A treatment. In the knockout hears this response
was over three- fold (316%) higher than that observed in the WT.
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Figure 2. Effects of AIR and A R stimulation on PP2A activities in pariculate and cytosolic
fractions of ventrcular myocardium from A R knockout (A RKO) murine hears. CGS (A
agonist) and CCP A (AIR agonist) are used at a concentration of 10- M. Data are means :: SE for
8 hears. * denotes statistically significant difference from respective control (Ctrl) value; 
denotes statistically significant difference from respective cytosolic value.
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Figure 3. Summar of changes in PP2A activity obsered in the particulate fraction of
ventrcular myocardium from WT and A RKO murine hearts with AIR and A R activation
(derived from data depicted in Figures lA and 2). CGS, 10- M; CCPA, 10- M. * denotes
statistically significant difference from WT value. See legends of Figues 1 and 2 for additional
details.
Distribution of PP2A activity between cytosolic and particulate fractions
Distrbution of the total activity between cytosolic and pariculate fractions (Fig 4) was
detennined by multiplying the protein nonnalized activity value for each sample by the total
volume of the fraction from which the analyzed sample was obtained. The resulting value is an
estimate of the total phosphatase activity of the fraction considered. This value was expressed as
a percentage of the sum of both cytosolic and pariculate fraction activities.
In the WT untreated hears the pariculate fraction (Fig 4A) was detennined to contain
10.9% ofthe total PP2A activity. With hears treated with CGS-21680 or CCP A the pariculate
fraction contained 9.5% and 12.4% oftotal PP2A activity, respectively. The value observed with
ZM-241385 was not different from the control value. The particulate fraction of A RKO hears
showed significantly lower total PP2A activities for both Ctrl and CGS-21680 groups (4.2% and
7% respectively) as compared to WT. On the other hand, CCP A-treated knockout hears , while
demonstrating a lower value in the pariculate fraction than their WT counterpars, displayed a
greater total PP2A activity (10.3%) compared with control.
The changes observed in the values for the cytosolic fraction (Fig 4B) follow a converse
pattern compared to the particulate fraction (Fig 4A). In WT hears the cytosolic fraction showed
greater total PP2A activities with CGS-21680 alone as well as with CCP A and CGS-2180
administered together. CCP A alone resulted in a reduced total PP2A activity. In the control and
CGS-21680 treated A RKO hears a higher total PP2A activity value was observed compared
with values found in WT hears, whereas the total PP2A activity with CCP A in A RKO hears
was lower. These data suggest that translocation ofPP2A activity between the cytosolic and
pariculate fractions is modulated by adenosinergic receptors in the hear.
Effect of AIR and A R activation on the phosphorylation state ofTyr 307 regulatory site
An ELISA assay was used to investigate whether the observed decrease in PP2A activity
in response to A R activation results from an increased phosphorylation at the Tyr 307
regulatory site, a known inhibitor ofPP2A activity (23) (Fig 5). In WT hearts CGS-21680 did
not effect the phosphorylation state ofTyr 307 site. However, treatment with CCPA caused a
35% increase in Tyr 307 site phosphorylation compared with that observed in control hears.
These findings suggest that the Tyr 307 regulatory site is unlikely to be directly involved in the
mediation ofthe presently observed effects of A R and AIR on PP2A activity.
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Figure 4. Effect of AIR and A
stimulation on the paritioning 
PP2A activity between pariculate
(Panel A) and cytosolic (Panel B)
fractions of ventrcular myocardium
from WT and A RKO murine
hears. CGS , CCP A and ZM are each
used at a concentration of 10-
Data are means :: SE for 4-9 hears. *
denotes statistically significant
difference from WT control (Ctrl)
value; t denotes statistically
significant difference from WT CGS
value; denotes statistically
significant difference from WT
CCP A value. See legends of Figues
1 and 2 for additional details.
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Figure 5. Effects of AIR and A R activation on the phosphorylation state of the Tyr 307
regulatory site ofPP2A in WT murne hears. ELISA assay was perfonned on ventrcular
myocardium homogenates from hears either untreated (control, Ctrl) or treated with CGS (10-
M) or CCP A (10- M). Data are means :I SE for 5 hears. * denotes significant difference from
Ctrl value. See legends of Figues 1 and 2 for additional details.
Discussion
Adenosinergic modulation of PP2A activity in WT and RKO
The main finding of the present study is that the level ofPP2A activity and its
localization within the ventrcular myocyte is modulated by the A R as well as the AIR. This
suggests that dephosphorylation of proteins important for contractile activity may playa role in
the manifestation of the anti adrenergic action of adenosine.
There is considerable support for a role of protein phosphatases in the regulation of
cardiac contractility. Overexpression ofthe catalytic subunit ofPP2A has been shown to impair
cardiac fuction in mice (20), whereas overexpression ofPPI-2 has been reported to enhance
cardiac contractility (24). The attenuation of protein phosphatase 1 (PPl) activity has been
demonstrated to enhance cardiac function in transgenic mice expressing PPI- l (38).
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Protein phosphatases have also been suggested to playa significant role in the
adenosinergic regulation of cardiac contractility. Narayan and colleagues have
pharacologically inhibited AIR anti adrenergic effects with the protein phosphatase inhibitor
canthardin (34) without significant changes in cAMP levels. Recently, Liu and colleagues have
provided evidence in isolated rat cardiomyocytes that the anti adrenergic effect of AIR is in part
mediated by the activation ofPP2A (29). This effect appeared to be transduced through p38
mitogen activated protein kinase (p38 MAK)(30). In agreement with these observations, acute
p38 MAK activation has been shown to decrease force development in rat ventrcular myocytes
(5), perhaps as a result of the dephosphorylation of proteins associated with contractile activity.
Protein phosphatase inibition with okadaic acid (OKA) has been demonstrated to foster
preconditioning in aged rat hears by a mechanism that may involve adenosine and is thought to
be mediated through changes in cardiac protein phosphorylation (17).
The observations from the present study support the previously reported findings of Liu
et al. suggesting that a significant fraction of the AIR anti adrenergic effect may be manifest via
protein phosphatase activity (29). In WT hears, activation of the AIR resulted in an increased
PP2A activity in both cytosolic (Fig. lA) and pariculate fractions (Fig. IB). On the other hand
activation of A R with CGS-21680 resulted in a decrease in PP2A activity in both fractions.
Even though the observable trends were the same in both pariculate and cytosolic fractions
changes in PP2A activities induced by A R and AIR were more prominent in the pariculate
fraction. The PP2A enzyme while mainly inactive in the cytosol may become activated upon
translocation to its intended destination as is seen with PKC (31). It might be assumed that the
higher PP2A activity in the pariculate fraction ensures the dephosphorylation of myocardial
proteins localized in this fraction.
Another finding of interest in the WT hears was the obsered effect of combined CCP A
and CGS-21680 on PP2A activity, where it was observed that PP2A activity was unchanged
from CGS-21680 alone. This suggests that CGS-21860 inhibits the AI induced increase in
PP2A activity. The ability of A R to act both directly and through inhibition of AIR effects has
been noted previously in contractile studies of both intact hears and isolated cardiomyocytes
(37 43).
In the A RKO hears (Fig. 2) AIR stimulation with CCP A resulted in a slightly higher
PP2A activity increase in the cytosolic fraction (16%) compared with WT (12%). However, in
the parculate fraction the increase in PP2A activity with CCP A administration was over two-
fold (205%). This observation correlates with previously reported findings that pharacological
inhibition of A R results in an enhanced response to AIR activation (37). Based on the present
observations it can be concluded that in the WT hear the A R would oppose the action of the
R in increasing PP2A activity, whereas in the A RKO this attenuation is absent resulting in
an exaggerated response to AIR stimulation. Curiously, CGS-21680 treatment of A RKO hears
resulted in a small but significant decrease of 7% in PP2A activity, an unexpected result in the
absence of A R protein. However, this finding was not replicable in the pariculate fraction.
The presence of A R may be important in detennining paritioning ofPP2A activity
within the cardiac myocyte. The relative distrbution ofPP2A activities between the pariculate
and cytosolic fractions with control and CGS-21680 treatment differs between WT and A RKO
hears. In the latter hearts , the PP2A activity levels in the pariculate fractions from both control
and CGS-21680 treated hears (Fig. 2) were significantly lower than those observed in the
cytosolic fraction. In comparson, WT control hears showed lower PP2A activity in the
cytosolic (Fig. IB) fraction, and with CGS-21680 PP2A activities were similar between cytosolic
and pariculate fractions. These observations suggest that the absence of A R signal may in
some way interfere with the PP2A activity as evidenced by the lower activity levels in the
pariculate fraction of A2ARKO hears. This conclusion is supported by the observation that in
both cytosolic and pariculate fractions of WT hears, PP2A activity is significantly reduced by
blockade of the A R with ZM-241385 (Fig. 1). However, this decrease does not appear to be as
profound as that observed in the A RKO. This observation may have resulted from incomplete
pharacological inhibition as compared with receptor absence. The particulate fraction of
RKO CCP A-treated hears displayed significantly higher (15%) PP2A activity than the
cytosolic fraction, an increase comparable to that seen in the WT. This suggests that despite the
decreased PP2A activity observed in the control A RKO hears, PP2A is stil able to effectively
become localized to the pariculate fraction and activated following AIR stimulation by CCP 
In brief, the changes occurng in PP2A activity with adenosinergic stimulation are most
readily compared in the pariculate fraction (Fig. 3). Within this fraction stimulation of A
with CGS-21680 resulted in a decrease ofPP2A activity in WT hearts , but not in A RKO
hears, whereas AIR activation had the opposite effect. In the A2 RKO hearts the response to
R was exaggerated, displaying a PP2A activity increase approximately threefold higher than
that observed in the WT hears. These findings suggest that both AIR and A R playa role in
modulating the activity ofPP2A.
Distribution of PP2A between the cytosolic and particulate fractions
In order to detennine whether AIR and A R stimulation affected the distrbution of total
PP2A activity between the cytosolic and particulate fractions, data was analyzed accounting for
the volume of sample in order to estimate the total activity present in each fraction. Significantly
enhanced localization of the total activity to the particulate fraction was observed in the CCP 
treated hears (Fig. 4A). This finding supports the observations made by Liu, et al. (29) who
previously reported translocation ofPP2A to the pariculate fraction of rat cardiomyocytes
following AIR activation. Furthennore, A R activation was observed to have the opposite effect
resulting in an enhanced localization ofthe total activity to the cytosolic fraction. Total PP2A
activities in both cytosolic and pariculate fractions were similar in the presence of CGS-21680
with or without CCP A. This indicates that the A R attenuates the actions of the AIR with
respect to PP2A localization as well as direct modulation of PP2A enzymatic activity as
discussed above.
Treatment ofWT hears with ZM-241385 did not result in significant changes in PP2A
localization compared with untreated hears, whereas actual enzyme activity was noted to be
decreased following ZM-241385 treatment (Fig. 1). This observation suggests that the decrease
in PP2A activity in the absence of A R protein or the inhibition by an A R antagonist may be
due to a decrease in enzymatic activity rather than altered localization of the enzyme within the
ventrcular myocyte.
Even though the greatest percentage of total PP2A activity is generally present in the
cytosolic fTaction, proteins associated with contractile fuction are localized in the pariculate
fraction. It is possible to argue that the changes in localization and activity ofPP2A observed in
the pariculate fraction are more reflective of adenosinergic influences on PP2A activity than
those changes occurrng in the cytosolic fraction.
Effect of AIR and A2 R activation on the Tyr 307 regulatory site of PP2A
The Tyr 307 regulatory site on PP2A is known to decrease the activity level of the
enzyme when phosphorylated (23). In order to investigate whether this is a mechanism by which
R or A R regulate the activity level of the PP2A enzyme, an ELISA assay was employed
using an antibody specific for the phosphorylated Tyr 307 ofPP2A (Fig. 5). No changes in Tyr
307 phosphorylation were observed with CGS-21680-induced A R activation. CCPA activation
of AIR resulted in a significant increase in the phosphorylation ofTyr 307. These results suggest
that the Tyr 307 site is unlikely to be involved in the adenosinergic regulation ofthe PP2A
enzyme. If this site is involved in the regulation of PP2A activity by AIR and A , an increased
Tyr 307 phosphorylation following A R activation and a decreased phosphorylation following
R activation would be expected. As this hypothesis is not supported by the present results, it is
concluded that other regulatory sites may be responsible for adenosinergic-mediated changes in
PP2A activity. The specific mechanism and sites for this regulation remain to be detennined.
In conclusion, this study indicates that A2AR as well as AIR modulate PP2A activity in
the ventrcular myocardium. These data indicate another mechanism by which adenosine
modulates contractile fuction in the presence and absence of BI-adrenergic stimulation. The
implications of adenosinergic receptor activation and their effects on protein phosphatases in the
regulation of myocardial contractility are summarzed in Figure 6 within the context of other
adenosinergic mediated events: 1. This mechanism involves activation and translocation of the
PP2A enzyme within the ventrcular myocyte to its site of action. AIR stimulation enhances
PP2A fuction via enzyme activation and/or translocation of enzyme to its active site while
R stimulation inhibits PP2A by either direct modulation of enzyme activity or translocation
or the inhibition of AIR effects on PP2A. 2. AIR and A R directly modulate adenylyl cyclase
activity (26) and subsequently cAMP content ofthe ventrcular myocyte (7). 3. A R activation
attenuates the AIR antiadrenergic action, indirectly enhancing contractile fuction (37 43).
Adenosinergic Influence on Phosphorylation
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Figure. 6. Schematic diagram depicting actions of AIR and A R in the modulation of cardiac
contractilty including suggested role of protein phosphatases. See text "Discussion" for details.
ADO: adenosine; TpI: troponin I; Plb: phospholamban.
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Supplemental Material
Additional preliminar study and supporting experiments for the preceding manuscript are
included in this section.
Optimal sample dilutionfor PP2A assay
In order to detennine the optimal dilution of the myocardial sample in tenns of observed
PP2A activity, the activity was measured is samples serially diluted by half in the
homogenization buffer. The myocardium was initially homogenized in 2 ml of homogenization
buffer. The resultant protein concentration in each dilution was detennined using a BCA assay
and the PP2A activity was plotted as a function of the protein concentration in each respective
dilution. The results are presented in supplementar Figue S5. As can be seen in the figue the
optimal sample concentration resulting in highest PP2A activity is between 10- 15 Ilg of protein
per assay. To maintain these optimal conditions in fuher experiments the myocardial
homogenate was diluted as appropriate to achieve the desired protein concentration.
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Figure S5. PP2A activity in a ventrcular myocardium sample as a factor of sample dilution.
Initially the sample is homogenized in 2 ml of homogenization buffer and then serially diluted by
half. The PP2A activity is assayed in each resulting sample concentration and plotted as a
function of the protein concentration in that paricular dilution.
PP2A activity response to vehicle and in vitro CGS-21680 treatment
To ascertain that DMSO which was the vehicle used for the administration of adenosine
receptor agents did not affect enzymatic activity, the activity of PP2A was assayed in ventrcular
myocardial extracts from hears treated with DMSO in concentration and duration similar to that
employed in the other experiments. In addition the effect of CGS-21680 treatment of the
homogenate as opposed to perfsion of the hear on PP2A was examined. Representative results
from a pair of these experiments are presented in supplementar Figure S6.
Neither in vitro CGS treatment nor DMSO treatment of the perfusing hear resulted in
significant changes of PP2A activity observed in the control group. From these observations it
can be concluded that DMSO at the concentrations used during administration of adenosinergic
agents does not have a significant impact on the activity ofPP2A. In addition it appears that the
inhbition ofPP2A activity by A R activation requires the intact cell and canot be reproduced
in the disrupted membranes present in the homogenate. This suggests that the transduction
pathway for the effects of A2 R on PP2A requires a proper spatial arangement of cellular
components as compared to such pathways as B-adrenergic activation of adenylyl cyclase which
readily occurs in myocardial membrane preparations (22).
12.
10.
:: -- 
() c:
CI .-
c( E
a. 0
a. D.
.e 
Figure S6. Representative results from experiments to examine PP2A activity in ventrcular
myocardium extracts either untreated (Ctrl) or treated with CGS-21680 (CGS , 10- M) in vitro
and extracts from hears treated with the vehicle (DMSO, 0.01 %) used for the adenosinergic
agents. Results presented are means :: SE for 2 hears.
Effect of in vitro adenosine treatment on PP2A activity
Myocardial homogenates, such as used in the study of adenosinergic modulation of PP2A
activity in the earlier presented study, may contain a significant amount of endogenous
adenosine. In most cases this can be remedied by the treatment of the preparation with adenosine
deaminase. However in the case of the present study it was desirable to avoid the addition of
reagents that were not critical to the assay. The possible direct effects of any endogenous
adenosine present in the preparation on PP2A activity were examined by subjecting the
ventrcular myocardial extract to 10- M adenosine in vitro. Results of this experiment are
presented in supplemental Figure S7. The PP2A activity observed following adenosine treatment
of the extract was not different from that observed in the control group which was untreated.
This observation indicates that adenosine affects the PP2A activity level via acting on the
appropriate adenosine receptors and adenosine on its own does not have a direct effect on the
PP2A enzyme.
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Figure S7. PP2A activity in ventrcular myocardium extracts either untreated (Ctrl) or treated 
vitro with adenosine (ADO , 10- M). Results are means :i SE for 5 hears.
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Inhibition of PP2A by assay conditions
One of the points of interest with regard to the type of phosphatase assay employed is
whether the assay conditions themselves cause some degree of inhibition of the phosphatase
activity. In order to study whether inhibition ofPP2A activity occurs as a result of assay
condition, a series of experiments was conducted utilizing added activity from the purified
catalytic subunit of PP2A enzyme (Promega, Madison, WI). The results of a representative
experiment are presented in supplementary Figue S8.
In the course ofthe experiment the phosphate released by PP2A activity in a myocardial
sample is compared between a "control group" where the sample is the only source of PP2A, and
an "added activity group" where a known amount of activity from the purified PP2A catalytic
subunit is also present. In theory if no inhibition of PP2A activity occurs, the combined
phosphate release should be additive between the added activity and the sample. In fact what is
seen is that the observed combined activity is slightly decreased from the estimated level
obtained by adding the known sample and added activities. This would suggest a mild inhibition
of the phosphatase by the conditions of the assay.
An alternate way of looking at the data is by comparng the estimated sample activity
based on the measured total activity and the measured added activity. In this scenaro subtracting
the known added activity from the total measured activity yield the expected activity in the
sample alone. This estimated activity though is lower than the actual sample activity observed.
This type of analysis would suggest the contrar: that inhibition ofPP2A does not occur.
A direct additive approach appears more appropriate and from that perspective a mild
inhibition ofPP2A activity appears to occur. Ultimately the level of inhibition observed is small
based on the difference in pmols of phosphate released and once the data is corrected for the
protein level as would occur in other experiments, the actual effect on the final PP2A activity
level expressed per minute and Jlg of protein becomes negligible. Based on these experiments it
is concluded that while a minor amount of inhibition does occur under the assay conditions, the
inhibition is present across all groups and does not prevent adequate comparson of differently
treated samples , nor does is significantly alter the findings of any experiments presented.
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Figure S8. Representative results from an experiment designed to examine whether the
conditions of the PP2A assay result in inhibiton of the phosphatase. Additional phosphatase
activity is added by supplementing the reaction mixtue with purfied catalytic subunit of PP2A.
Estimated total activity is the sum of measured basal and added activities. Calculated basal
activity is obtained by takng the measured Total activity and subtracting the added activity. *
denotes significant difference from the Total activ.(measured) value. t denotes significant
difference from Basal activ. (measured) value.
Summary of Key Findings
1) A R as well as AIR is able to affect the activity ofPP2A.
2) A R stimulation results in decreased PP2A activity as well as enhanced localization of the
enzyme to the cytosolic fraction. AIR has the opposite effect resulting in increased PP2A activity
and enhanced localization to the pariculate fraction.
3) A R activation appears to block the effects of AIR-mediated increase in PP2A activity and
localization.
4) In the A R knockout animals, PP2A activity increase observed with AIR activation is greater
suggesting an inhibitory influence of A R on AIR with respect to modulation of phosphatase
acti vi ty.
5) The presence of the A R is required for normal baseline PP2A function as evidenced by
decreased PP2A activity and decreased pariculate fraction localization in the A R knockout
animals. These observations are supported by phannacological inhibition of A R as well.
6) Despite the alterations in baseline function observed in the A R knockout, the PP2A enzyme
is able to activate and localize appropriately upon AIR stimulation.
Comprehensive Discussion
Rationale r stu adenosine ic effects in the heart
The main reason for investigation into the adenosinergic signaling within the hear is that
this pathway plays a major role in regulating myocardial contractility and response to adrenergic
stimulation (16 18-20). The contractile study presented earlier presents the main findings in the
murine hear with respect to adenosinergic effects on the contractility in the intact isolated hear
(88).
In addition to regulation of contractilty adenosinergic signaling is also involved in both
response to acute pathological events (33 99) as well as chronic conditions (34 80).
The modulation of the effects of adenosine receptor signaling may fonn the basis of treatment
strategies relying on either pharacological or perhaps genetic manipulation of these effects. An
additional benefit to the utilization of adenosinergic signaling as a possible therapeutic pathway
is that the adenosinergic effects occur in parallel with the main adrenergic-cholinergic regulation
pathway and as such can provide the desired alterations in cardiac function without directly
interfering in adrenergic-cholinergic signaling, and with less systemic side effects. This avenue
of approach could be useful in conjunction with existing pharacological treatments for
pathological conditions such as heart failure where an increase in contractility is desired, or
provide an approach where existing conventional treatments are ineffective as in the case of
treatment of resistant hypertension.
The study of adenosinergic regulation of cardiac contractilty is paricularly convenient 
the murine model for several reasons. Curent technology allows the monitoring of virtally all
the hemodynamic and cardiovascular parameters that can be monitored in a human patient.
Combined with reasonable breeding and upkeep costs the murine model is highly valuable and
adaptable model for both in vitro and in vivo experments. In addition the use of specific receptor
knockout genotypes such as the A R knockout (7), allows for even more intrcate investigation
into the effects of individual adenosine receptors. The availability of murine models of
pathological conditions like hear failure (80) and overload hypertophy (9 70) makes initial
testing of clinical applications feasible in the murine model.
Summary ofkev findings in contractile studies of isolated murine hearts
The main finding ofthe present study is that in the murine heart AIR and A R regulate
the contractile response to B-adrenergic stimulation by manifesting opposite effects. As
previously observed in the rat model the AIR decreases the contractile response to B-adrenergic
stimulation (66 78), while A R attenuates the AIR effect and also increases contractility directly
(20 96).
From the perspective of an isolated hear it is not possible to directly address what the
mechanism behind the A2AR-mediated AIR inhibition is, however it is possible that the
modulation of phosphatase activity as described in the earlier presented study may be a par of
that interaction. The adapted scheme of adenosinergic influence on contractility in the hear as
outlined in the contractile study is summarzed in Figure C.
An additional finding ofthe study was the effect of A R activation in the setting oflow
flow ischemia. A R activation was noted to significantly maintain contractile fuction of the
hear despite decreased levels of perfusion. The response to a short tenn actuate flow decrease
was also found to be reduced following A R activation. This suggests a cardioprotective effect
of A R that may be related to mechanisms involved in preconditioning, (72 92) or may be the
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result of increased phosphorylation of proteins important in contractile fuction (47 57) or
enhanced adenylyl cyclase activation (11 22).
Interestingly the observed response of A2AR knockout hears to AIR activation was less
than that observed in the wild type suggesting that perhaps in the knockout some level of
compensation occurs for the absence of A , as phannacological inhibition of the AzAR has
been reported to actually increase the response to AIR activation (78) and PP2A activity
response to AIR activation in the knockout is also enhanced. It is possible that this observation is
due to an alteration in the response of adenyl ate cyclase in the A2 R knockout environment, a
concept addressed in further detail in the "futue directions" section.
Adenosinergic Modulation of Cardiac Contractility
Figure C. A schematic of
adenosinergic modulation
of contractile response to
B-adrenergic stimulation in
the hear. Adrenergic
stimulation results in
release of adenosine within
the myocardium which in
tu activates the AIR and
R. The anti adrenergic
effect of AIR results in
decreased contractility,
while A R both increases
contractility directly as well
as modulated the effects of
ADO
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Summary of key findings in studies of vrotein phosphatase 2A activity modulation bv adenosine
41 and A JA receptors
The major finding ofthis study is that A R as well as AIR is able to modulate the
activity ofPP2A. Like the previously described modulation ofPP2A activity by AIR (61), the
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R is able to affect both activity of the enzyme as well as its localization within the cellular
fractions. This indicates that both the activity level of the enzyme itself and its location within
the cell playa role in regulating the overall activity.
In hears treated with agonists for both AIR and A R the observed PP2A activity was
similar to those treated with AzAR agonist alone. The apparent ability of AzAR activation to block
to stimulatory effects of AIR on PP2A may be responsible for the observed "indirect effect"
described in the contractile studies. If the direct effect of A R is related to enhanced activation
of adenyl ate cyclase and subsequent increase in cellular cAMP , the decrease in PP2A activity
with A R which is not directly related to cAMP levels may account for the observed increase in
contractility with A R activation even in the absence oflarge increases in cAMP levels. Further
study is needed to determine the relative contrbution of each of these effects to the regulation of
contractilty in the hear. Interestingly, in the R knockout the PP2A activity was reduced in
the pariculate fraction under baseline conditions as well as in the presence of A R agonist
suggesting that the presence of A2AR plays a role in the nonnal activation and translocation of
PP2A to its location of activity. Pharacological deactivation of A R resulted in similar albeit
less pronounced results. The precise fuction of the A R to necessitate its presence for nonnal
baseline PP2A activity in the resting state remains to be detennined.
Wild type and A JAR knockout model in studv of cardiac contractilty
Having established the main effects of adenosine in wild type animals and examined
responses in A R knockout animals as well, the murne hear model can now be used as a
platfonn for a varety of directions for futue research. The most interesting prospective avenues
of study are discussed in more detail in the "future directions" section but briefly the existing
findings lay the foundations for amongst other things, identification of new adenosinergic agents
that are more specific for desired receptors and also synthesis of tissue selective targeting
approaches for pharacological agents; additional study of the impact of protein phosphatases in
the regulation of myocardial contractility; the exploration of possible differences in adenylyl
cyclase function and response to B-adrenergic stimulation between the wild type and A
knockout animals; long ter effect of A R knockout or inhbition on the general functioning of
the hear and responses to adrenergic stimuli, and lastly the involvement of adenosine receptors
in preconditioning and pathways that are responsible for these effects.
Considerations in use of knockout animal models
Certain factors must be considered when utilizing a receptor knockout animal model.
Beyond the basic considerations with respect to viabilty of the animals to a specific age and
their ability to reproduce there may be unforeseen effects of receptor deletion that can alter or
even interfere with experimental results. However, even the basic considerations of breeding
may pose a challenge to successfully obtaining viable knockout animals for studies. For
example, the A R knockout animals used in the present study tend to become obese especially
at over 6 months of age. While used at a much younger age for the experiments described in the
presented studies, even those animals heterozygous for the A R knockout gene would readily
become obese when given the increased fat diet typically used for breeders. This would in 
result in decreased litter sizes and at times even failure to produce litters. Use ofthe standard diet
for the breeders alleviated the problem.
In addition to logistical issues, working with a knockout model presents the challenge of
interpreting the experimental results with consideration of possible global effect of the absence
of the receptor. The A R knockout mice are known to exhibit increased hear rate and blood
pressure (97) while also manifesting altered characteristics with respect to manifestation of
ischemic damage (7) and binding properties of receptor agents (64 88). The enhanced effects of
R activation on PP2A activity as observed earlier in the discussion provide evidence that
receptor function and their effects may indeed be different in the absence of other receptors that
nonnally a par of the interaction. Finally, a recent study has shown that adenosine AIR deletion
may have effects on the expression of other adenosine receptors (76).
Many of these alterations may not significantly change the results of experiments
designed for the elucidation of receptor fuction and transduction pathways for the effects of the
receptors, however, these differenced between wild type and knockout animals need to be
carefully considered ifthe knockout animals are used to design a treatment or clinical
application. While a knockout model is highly useful in exploring the possible interactions
between receptor subtypes, or efficiency of pharacological agents with respect to adenosine
receptors, it would be highly advisable to use wild type animals in studies where the goal is to
examine the usefulness of receptor action in a more physiologically realistic situation. On the
other hand, in considering applications involving long tenn alteration of receptor physiology
such as gene therapy or long tenn agonist/antagonist treatment, the long tenn results of receptor
deletion in the knockout animal model would be of high value as it would be the best available
predictor of the long tenn consequences of proposed intervention.
Future Directions
Based on the findings of the preceding studies, there are a number of avenues for
continued research to further elucidate the role of adenosine receptors in regulation of cardiac
fuction paricular contractilty. In addition, several aspects of the myocardial response to
adenosinergic stimulation may be useful clinically and as such may fonn a basis for treatment of
relevant cardiac dysfuction. This section addresses firstly the aspects that merit fuher
investigation from a basic science perspective, with respect to finer mechanisms of adenosine
receptor action and co-regulation. Following is a section addressing the possible clinical
implications of the findings and possible avenues of investigation to examine the usefulness of
the observed responses in context of pathological conditions.
Basic Science:
Regulation of PP2A by A
Having demonstrated the abilty of the A R to modulate PP2A activity, the next logical
steps would be to detennine the mechanism by which the receptor affects the PP2A and what
specific changes the phosphatase undergoes in the process of this regulation. As previously
discussed it appears that the Tyr 307 site is not directly involved in regulation ofPP2A activity
by A R. There are several sites that are also known for altering PP2A activity and may be
responsible for mediating the A R effect. In addition to the Tyr 307 site examined in the present
study, the activity of the PP2A can be altered by methylation of the catalytic subunit as well as
phosphorylation of other regulatory subunits (43). In order to detennine the specific alterations
ofthe PP2A enzyme, myocardial samples ofPP2A can be tested with specific antibodies
examining the states of the other known regulatory sites. Sites that result in PP2A deactivation
and appear to be appropriately altered following A R activation would become likely
candidates for the mediation of A R effects.
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To ensure the specificity of this pathway to the A , the experiments can be repeated in
an AIR knockout animal. Results from this type of investigation may also yield infonnation
about the interaction of the AIR and A R at this co-regulatory point. As noted previously the
R effects on PP2A appear to be greater in the A R knockout animals suggesting an inhibitory
effect of A R on AIR. If the AIR knockout displays a response to A R stimulation that is
significantly altered from that observed in the wild type, the finding may suggest that AIR can
modulate the effects of A R as well.
In addition to the alterations to the PP2A enzyme itself, the pathway mediating the signal
leading to that alteration is also of interest. A reasonable staring point would be to examine
whether the p38 MAK pathway previously reported to mediate AIR activation ofPP2A is also
influenced by the A R. The simplest way to accomplish this would be to examine whether acute
R activation results in p38 MAK dephosphorylation. A more circumferential approach that
may be used to verify ths finding would be to arificially phosphorylate p38 MAK in a tissue
sample or activate it via guanylyl cyclase in an A R knockout animal. If this results in
alterations in PP2A activity similar to those observed on the wild type animal following A
activation, then that observation would be consistent with the pathway being involved in the
regulation of PP2A.
Regulation of PP by A R and Ai
Along with PP2A, PPI is the other phosphatase mainly responsible for
dephosphorylations of cardiac proteins. It would be interesting to ascertain whether PP 1 activity
is also modulated by adenosinergic pathways. An initial approach would be the repetition of
experiments similar to those presented earlier in the study of PP2A. An appropriate substrate and
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optimized assay conditions would allow a relatively easy survey of possible AIR and A
effects on the activity ofPPl. Ifindeed such effects are observed, fuher detailed infonnation
may be obtained by more focused studies utilizing AIR or A R knockouts as appropriate. The
pathways responsible for the transduction of the signal would also be of interest in the case of
positive initial findings.
Adenylyl cyclase activity in A R knockout
During the study of adenosinergic modulation ofPP2A activity it was noted that in the
absence of A R signal (as seen in the knockout) the response to AIR stimulation was enhanced
suggesting that A R has an inhibitory effect on AIR. Enhanced effect of AIR activation was
also observed following pharacological inhibition of A R in previous a previous study of
contractility in rat hearts (78). These findings raise the question of whether a similar
phenomenon occurs with respect to adenylyl cyclase activation. It would be of interest whether
the decrease of adenylyl cyclase activity following AIR activation in an A R knockout animal is
greater compared with the wild type. The observed enhanced response to AIR activation in the
R knockout may be due to effects on adenylyl cyclase or another pathway such as activation
of PP2A.
In the course of earlier presented contractile studies in isolated mouse hears , it was noted
that the response of the A R knockouts to AIR activation was not as pronounced as that seen in
the wild type. The reason for that finding is not entirely clear, as the contrar finding was
previously reported, and present studies of adenosinergic modulation PP2A activity also reveled
greater effect of AIR in the absence of A2 R. A possible rationale for the observed decreased
responsiveness to AIR stimulation in the contractile studies (assuming it is not an isolated
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finding) may be a desensitization of adenylyl cyclase to the Gi mediated inhibitory signal of AI
activation. It is possible that in the absence of A R signal, the AIR influence alone would result
in bradycardia or even hear block if unopposed. This type of detrmental effect could in theory
be countered by decreased sensitivity of adenylyl cyclase to AIR stimulation. If this is the case it
would explain the observations made during the present contractile studies in AZAR knockouts.
The effect of AIR activation on adenylyl cyclase activity can be readily assessed by assay of
cAMP fonned in tissue extracts from wild tye or R knockout myocardium.
Direct interaction between AiR and A
The present studies have shown that AIR and A R have several focal point of co-
regulation. Modulation of adenylyl cyclase activity has been thought the "classical" mechanism
of the opposing influences of AIR and A , but protein phosphatase has also been shown to
play an important role in this process. With the knowledge that there are multiple pathways and
levels of interaction between these two adenosine receptors, it is curous whether in addition to
downstream regulatory effects , these receptors have a more direct co-regulatory relationship. The
question that follows is whether the AIR and A R receptors have a direct membrane linkage
that alters the binding affnity of either receptor based on the activation state ofthe other.
An initial method of investigation would be immunoprecipitation studies directed at
selectively precipitating the AIR or A R in myocardial homogenate preparations. Following
immunoprecipitation the resulting product would be probed for the presence of both the receptor
targeted by the antibody as well as the other receptor of interest. If AIR and A R are found to
co-precipitate that may suggest that a membrane linkage may exist between the two. Furher
anal ysis of the related proteins may be accomplished via mass spectrometr to identify candidate
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proteins. As an advanced step, the importance of these candidate proteins to the co-regulation of
the AIR and A R maybe verified by creating a genetic knockout of the protein in question, or
selectively inhibiting expression of the proteins in question using siRNA techiniques if a tissue
culture approach is preferred.
An alternate way to begin approaching the issue would be to examine whether the
activation state ofthe AIR and A2A , affects the binding affinity for appropriate radiolabeled
agonist or antagonist. This type of study may give an initial indication of whether activation of
either receptor has a direct effect on its counterpar. The absence of findings in these experiments
would suggest that direct interaction between AIR and A R is unlikely and the interaction of
their effects occurs downstream of receptor activation. Positive findings however would
eventually require an approach such as outlined above in order to elucidate the exact natue of
receptor interaction.
Clinical Applications:
R selective maintenance of contractility in acute heart failure
As noted in the contractile studies previously described, one of the effects of A
activation is enhancement of contractility in the presence of reduced blood flow.
It may be possible to make use of this effect to support the contractile function of the hear
durng an acute event such as myocardial ischemia or hypovolemic shock. In both of these
conditions the primar concern is the inadequate blood flow to the myocardium whether local or
global.
The use of a reversible A R agonist may provide support for the myocardium for the
period of time necessar to enact treatment of the underlying condition. This type of application
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can be tested using a rodent model oflocal myocardial ischemia or hypovolemic shock. Both of
these conditions are readily replicated and the rodent model would allow for easy administration
of the receptor agonist as well as monitoring of the response.
A2A induced vasodilation to treat local ischemia acutely or post-acutely
One of the most readily notable effects of A R activation is the coronary vasodilation it
causes. This effect may be useful to produce vasodilation during procedures such as angioplasty
where the goal is to restore flow to myocardium following restoration of patency in a previously
occluded vessel. Local administration of a selective A R agonist may produce vessel relaxation
and enhanced flow to the previously ischemic region. This approach may be combined with
techniques such as gradual or "stuttered" reperfsion in order to minimize reperfsion injury to
the myocardium. The vasodilatory effect of A R may also be useful on a chronic level if a low
dose agonist is released from the stent placed following angioplasty. The vasodilatory effect may
contrbute to enhanced flow to regional myocardium and decreased risk of post procedure
thrombosis of the stent site. These applications are possible to test using a larger test model
(canine or porcine) where the coronary vasculature may be used to simulate conditions and
procedures present during catheterization in the human hear.
Protein phosphatase manipulation to treat chronic heart failure
The observed inhibitory effects of A R on PP2A suggest that reduced
dephosphorylation of proteins important in contractile function contrbutes to enhanced
contractile response observed with A R activation. These observations combined with the
results of previous studies showing enhanced contractility in hears overexpressing phosphatase
104
inhibitors suggest that inhibition of PP 1 or PP2A may be a fuctional therapeutic approach to
treat chronic heart failure. Initial testing of this methodology may be accomplished by using a
murine model of heart failure induced by pressure overload achieved by aortic banding. A
phosphatase inhibitor of choice may be administered to one group of animals and the progression
of heart failure in that group compared to a control group that is not treated with the inhibitor.
Slowed progression of hear failure would suggest that this approach can possibly be used to
treat the progression of hear failure occurng from natual causes.
The problem of selective targeting ofthe phosphatase inhibitor may eventually be solved
by utilzing gene therapy as opposed to direct administration of phosphatase antagonists. If it
were possible to selectively induce expression of a phosphatase inhibitor in the myocardium , the
resultant increase in contractile fuction could be beneficial to treat end stage chronic hear
failure perhaps improving effcacy of a ventrcular assist device or providing additional time to
acquire a transplant.
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